AU6934194A - Antibodies - Google Patents

Antibodies

Info

Publication number
AU6934194A
AU6934194A AU69341/94A AU6934194A AU6934194A AU 6934194 A AU6934194 A AU 6934194A AU 69341/94 A AU69341/94 A AU 69341/94A AU 6934194 A AU6934194 A AU 6934194A AU 6934194 A AU6934194 A AU 6934194A
Authority
AU
Australia
Prior art keywords
antibodies
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
AU69341/94A
Other versions
AU691811B2 (en
Inventor
Diljeet Singh Athwal
Mark William Bodmer
John Spencer Emtage
Susan Adrienne Morgan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Celltech R&D Ltd
Original Assignee
Celltech R&D Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to GB939312415A priority Critical patent/GB9312415D0/en
Priority to GB9312415 priority
Priority to GB9401597A priority patent/GB9401597D0/en
Priority to GB9401597 priority
Priority to GB9402499 priority
Priority to GB9402499A priority patent/GB9402499D0/en
Priority to GB9406244A priority patent/GB9406244D0/en
Priority to GB9406244 priority
Priority to PCT/GB1994/001290 priority patent/WO1994029351A2/en
Application filed by Celltech R&D Ltd filed Critical Celltech R&D Ltd
Publication of AU6934194A publication Critical patent/AU6934194A/en
Assigned to CELLTECH THERAPEUTICS LIMITED reassignment CELLTECH THERAPEUTICS LIMITED Amend patent request/document other than specification (104) Assignors: CELLTECH LIMITED
Application granted granted Critical
Publication of AU691811B2 publication Critical patent/AU691811B2/en
Anticipated expiration legal-status Critical
Application status is Ceased legal-status Critical

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2833Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732Antibody-dependent cellular cytotoxicity [ADCC]
AU69341/94A 1993-06-16 1994-06-15 Antibodies Ceased AU691811B2 (en)

Priority Applications (9)

Application Number Priority Date Filing Date Title
GB939312415A GB9312415D0 (en) 1993-06-16 1993-06-16 Altered antibodies
GB9312415 1993-06-16
GB9401597A GB9401597D0 (en) 1994-01-27 1994-01-27 Altered antibodies
GB9401597 1994-01-27
GB9402499 1994-02-09
GB9402499A GB9402499D0 (en) 1994-02-09 1994-02-09 Altered abtibodies
GB9406244 1994-03-29
GB9406244A GB9406244D0 (en) 1994-03-29 1994-03-29 Altered antibodies
PCT/GB1994/001290 WO1994029351A2 (en) 1993-06-16 1994-06-15 Antibodies

Publications (2)

Publication Number Publication Date
AU6934194A true AU6934194A (en) 1995-01-03
AU691811B2 AU691811B2 (en) 1998-05-28

Family

ID=27451034

Family Applications (1)

Application Number Title Priority Date Filing Date
AU69341/94A Ceased AU691811B2 (en) 1993-06-16 1994-06-15 Antibodies

Country Status (5)

Country Link
EP (1) EP0714409A1 (en)
JP (1) JPH08511420A (en)
AU (1) AU691811B2 (en)
CA (1) CA2163345A1 (en)
WO (1) WO1994029351A2 (en)

Families Citing this family (701)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) * 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5985599A (en) * 1986-05-29 1999-11-16 The Austin Research Institute FC receptor for immunoglobulin
US5824307A (en) 1991-12-23 1998-10-20 Medimmune, Inc. Human-murine chimeric antibodies against respiratory syncytial virus
EP0753065B1 (en) 1994-03-29 2003-05-14 Celltech Therapeutics Limited Antibodies against e-selectin
US7803904B2 (en) 1995-09-01 2010-09-28 Millennium Pharmaceuticals, Inc. Mucosal vascular addressing and uses thereof
US7247302B1 (en) 1996-08-02 2007-07-24 Bristol-Myers Squibb Company Method for inhibiting immunoglobulin-induced toxicity resulting from the use of immunoglobulins in therapy and in vivo diagnosis
US7147851B1 (en) 1996-08-15 2006-12-12 Millennium Pharmaceuticals, Inc. Humanized immunoglobulin reactive with α4β7 integrin
EP1042505A1 (en) * 1997-12-22 2000-10-11 Cockbain, Julian Method for disease prognosis based on fc receptor genotyping
US6242195B1 (en) 1998-04-02 2001-06-05 Genentech, Inc. Methods for determining binding of an analyte to a receptor
US6528624B1 (en) 1998-04-02 2003-03-04 Genentech, Inc. Polypeptide variants
DE69937291T2 (en) * 1998-04-02 2008-07-10 Genentech, Inc., South San Francisco Antibody variants and fragments thereof
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
GB9809951D0 (en) * 1998-05-08 1998-07-08 Univ Cambridge Tech Binding molecules
CN1237076C (en) 1999-01-15 2006-01-18 杰南技术公司 Polypeptide variants with altered effector function
US7183387B1 (en) 1999-01-15 2007-02-27 Genentech, Inc. Polypeptide variants with altered effector function
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
CN1360596A (en) 1999-02-12 2002-07-24 遗传研究所有限公司 Humanized immunoglobulin reactive with B7 molecules and methods of treatment therewith
US6972125B2 (en) 1999-02-12 2005-12-06 Genetics Institute, Llc Humanized immunoglobulin reactive with B7-2 and methods of treatment therewith
BR0110610A (en) 2000-04-11 2003-04-29 Genentech Inc isolated antibodies, immunoconjugates, polypeptide chains, isolated nucleic, vector, host cell acid, antibody production process or polypeptide chain, dysfunctions method of treating in a mammal, method of inducing apoptosis in a cancer cell, the method for killing a b cell method to kill a cell that expresses an erbB receptor and uses of isolated antibodies
US7416726B2 (en) 2000-04-13 2008-08-26 The Rockefeller University Enhancement of antibody-mediated immune responses
US20010046496A1 (en) 2000-04-14 2001-11-29 Brettman Lee R. Method of administering an antibody
PT1283214E (en) 2000-04-21 2007-03-30 Fuso Pharmaceutical Ind Novel collectins
CA2410458A1 (en) 2000-06-08 2001-12-13 The Center For Blood Research, Inc. Methods and compositions for inhibiting immunoglobulin-mediated__reperfusion injury
US7179892B2 (en) 2000-12-06 2007-02-20 Neuralab Limited Humanized antibodies that recognize beta amyloid peptide
DE60143544D1 (en) 2000-12-12 2011-01-05 Medimmune Llc Molecules with longer mid-term, compositions and their use
US7658921B2 (en) 2000-12-12 2010-02-09 Medimmune, Llc Molecules with extended half-lives, compositions and uses thereof
JP4461210B2 (en) 2001-08-27 2010-05-12 ジェネンテック, インコーポレイテッド Antibody expression system and its construction
KR20050036852A (en) 2001-10-15 2005-04-20 기린 비루 가부시키가이샤 Anti-hla-dr-antibody
US7053202B2 (en) 2001-10-19 2006-05-30 Millennium Pharmaceuticals, Inc. Immunoglobulin DNA cassette molecules, monobody constructs, methods of production, and methods of use therefor
US8388955B2 (en) 2003-03-03 2013-03-05 Xencor, Inc. Fc variants
US7662925B2 (en) 2002-03-01 2010-02-16 Xencor, Inc. Optimized Fc variants and methods for their generation
US8084582B2 (en) 2003-03-03 2011-12-27 Xencor, Inc. Optimized anti-CD20 monoclonal antibodies having Fc variants
US8188231B2 (en) 2002-09-27 2012-05-29 Xencor, Inc. Optimized FC variants
US9051373B2 (en) 2003-05-02 2015-06-09 Xencor, Inc. Optimized Fc variants
US7317091B2 (en) 2002-03-01 2008-01-08 Xencor, Inc. Optimized Fc variants
US9714282B2 (en) 2003-09-26 2017-07-25 Xencor, Inc. Optimized Fc variants and methods for their generation
US20090010920A1 (en) 2003-03-03 2009-01-08 Xencor, Inc. Fc Variants Having Decreased Affinity for FcyRIIb
US7132100B2 (en) 2002-06-14 2006-11-07 Medimmune, Inc. Stabilized liquid anti-RSV antibody formulations
US8968730B2 (en) 2002-08-14 2015-03-03 Macrogenics Inc. FcγRIIB specific antibodies and methods of use thereof
US8530627B2 (en) 2002-08-14 2013-09-10 Macrogenics, Inc. FcγRIIB specific antibodies and methods of use thereof
US8187593B2 (en) 2002-08-14 2012-05-29 Macrogenics, Inc. FcγRIIB specific antibodies and methods of use thereof
US8946387B2 (en) 2002-08-14 2015-02-03 Macrogenics, Inc. FcγRIIB specific antibodies and methods of use thereof
US8101720B2 (en) 2004-10-21 2012-01-24 Xencor, Inc. Immunoglobulin insertions, deletions and substitutions
US20040132101A1 (en) * 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
AU2008229860B2 (en) * 2003-05-02 2012-01-12 Xencor, Inc Optimized Fc variants and methods for their generation
AU2006299429B2 (en) 2005-10-03 2012-02-23 Xencor, Inc. Fc variants with optimized Fc receptor binding properties
WO2004074430A2 (en) * 2002-12-06 2004-09-02 Diadexus, Inc. Compositions, splice variants and methods relating to lung specific genes and proteins
US7960512B2 (en) 2003-01-09 2011-06-14 Macrogenics, Inc. Identification and engineering of antibodies with variant Fc regions and methods of using same
JP2006524039A (en) 2003-01-09 2006-10-26 マクロジェニクス,インコーポレーテッド Identification and production of antibody containing mutant Fc region and use thereof
CN102040662A (en) 2003-03-14 2011-05-04 医学免疫有限公司 Antibodies against human IL-21 receptor and uses therefor
NZ544924A (en) 2003-06-27 2009-03-31 Biogen Idec Inc Modified binding molecules comprising connecting peptides
NZ545776A (en) 2003-08-22 2009-05-31 Biogen Idec Inc Improved antibodies having altered effector function and methods for making the same
US20050191293A1 (en) 2003-12-10 2005-09-01 Shrikant Deshpande IP-10 antibodies and their uses
EP2135619A1 (en) 2003-12-10 2009-12-23 Millennium Pharmaceuticals, Inc. Humanized anti-CCR2 antibodies and methods of use therefor
DK2418220T3 (en) 2003-12-10 2017-11-06 Squibb & Sons Llc Interferon-alpha antibodies and applications thereof
EP2275448A3 (en) 2003-12-19 2013-02-06 Genentech, Inc. Monovalent antibody fragments useful as therapeutics
AT437184T (en) * 2004-01-12 2009-08-15 Applied Molecular Evolution Variants of fc region
EP2290077B1 (en) 2004-03-01 2016-01-27 Immune Disease Institute, Inc. Natural IGM antibodies and inhibitors thereof
CA2561533C (en) 2004-04-13 2015-06-16 Yvo Graus Anti-p-selectin antibodies
EP1761563A4 (en) 2004-05-10 2008-05-14 Macrogenics Inc HUMANIZED Fc gamma RIIB SPECIFIC ANTIBODIES AND METHODS OF USE THEREOF
SI2662390T1 (en) 2004-06-21 2017-10-30 E. R. Squibb & Sons, L.L.C. Interferon alpha receptor 1 antibodies and their uses
EP2399936A3 (en) 2004-07-26 2012-02-22 Biogen Idec MA Inc. Anti-CD154 antibodies
PL1776384T3 (en) 2004-08-04 2013-10-31 Mentrik Biotech Llc Variant fc regions
PL1773885T3 (en) 2004-08-05 2010-09-30 Genentech, Inc. Humanized anti-cmet antagonists
CA2577329A1 (en) 2004-08-16 2006-03-02 Medimmune, Inc. Eph receptor fc variants with enhanced antibody dependent cell-mediated cytotoxicity activity
RS57636B1 (en) 2004-09-03 2018-11-30 Genentech Inc Humanized anti-beta7 antagonists and uses therefor
US7700099B2 (en) 2005-02-14 2010-04-20 Merck & Co., Inc. Non-immunostimulatory antibody and compositions containing the same
US7632497B2 (en) 2004-11-10 2009-12-15 Macrogenics, Inc. Engineering Fc Antibody regions to confer effector function
US8546543B2 (en) 2004-11-12 2013-10-01 Xencor, Inc. Fc variants that extend antibody half-life
US8367805B2 (en) 2004-11-12 2013-02-05 Xencor, Inc. Fc variants with altered binding to FcRn
KR101019525B1 (en) 2004-11-12 2011-03-07 젠코어 인코포레이티드 Fc VARIANTS WITH ALTERED BINDING TO FcRn
US8802820B2 (en) 2004-11-12 2014-08-12 Xencor, Inc. Fc variants with altered binding to FcRn
ES2557325T3 (en) 2004-12-28 2016-01-25 Innate Pharma S.A. Monoclonal antibodies against NKG2A
KR101289537B1 (en) 2005-02-15 2013-07-31 듀크 유니버시티 Anti-cd19 antibodies and uses in oncology
NZ561883A (en) 2005-03-23 2010-11-26 Genmab As Antibodies against CD38 for treatment of multiple myeloma
ES2707152T3 (en) 2005-04-15 2019-04-02 Macrogenics Inc Covalent diabodies and uses thereof
US9284375B2 (en) 2005-04-15 2016-03-15 Macrogenics, Inc. Covalent diabodies and uses thereof
US9963510B2 (en) 2005-04-15 2018-05-08 Macrogenics, Inc. Covalent diabodies and uses thereof
CA2606102C (en) 2005-04-26 2014-09-30 Medimmune, Inc. Modulation of antibody effector function by hinge domain engineering
CA2607281A1 (en) 2005-05-05 2006-11-16 Duke University Anti-cd19 antibody therapy for autoimmune disease
CA2970873A1 (en) 2005-05-09 2006-11-16 E. R. Squibb & Sons, L.L.C. Human monoclonal antibodies to programmed death 1 (pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics
EA019344B1 (en) 2005-07-01 2014-03-31 МЕДАРЕКС, Эл.Эл.Си. Human monoclonal antibodies to programmed death ligand 1 (pd-l1) and uses thereof
AU2006265936A1 (en) 2005-07-01 2007-01-11 Medimmune, Llc An integrated approach for generating multidomain protein therapeutics
EP1910836B1 (en) 2005-07-21 2014-11-26 Genmab A/S Potency assays for antibody drug substance binding to an fc receptor
LT2573114T (en) 2005-08-10 2016-10-10 Macrogenics, Inc. Identification and engineering of antibodies with variant Fc regions and methods of using same
AU2006302254B2 (en) 2005-10-06 2011-05-26 Xencor, Inc. Optimized anti-CD30 antibodies
JP2009511067A (en) 2005-10-14 2009-03-19 メディミューン,エルエルシー Cell presentation of antibody libraries
AU2006303452B2 (en) 2005-10-21 2011-06-09 Novartis Ag Human antibodies against IL13 and therapeutic uses
EP2465870A1 (en) 2005-11-07 2012-06-20 Genentech, Inc. Binding polypeptides with diversified and consensus VH/VL hypervariable sequences
EP2623516B1 (en) 2005-12-02 2015-07-15 Genentech, Inc. Compositions and methods for the treatment of diseases and disorders associated with cytokine signaling involving antibodies that bind to il-22 and il-22r
EP1957540B1 (en) 2005-12-02 2012-06-13 Genentech, Inc. Binding polypeptides and uses thereof
SI1960434T1 (en) 2005-12-08 2012-11-30 Medarex Inc Human monoclonal antibodies to fucosyl-gm1 and methods for using anti-fucosyl-gm1
US7763245B2 (en) 2005-12-15 2010-07-27 Genentech, Inc. Methods and compositions for targeting polyubiquitin
EP3156418A1 (en) 2006-01-05 2017-04-19 Genentech, Inc. Anti-ephb4 antibodies and methods using same
ES2586825T3 (en) 2006-01-12 2016-10-19 Alexion Pharmaceuticals, Inc. Antibodies for OX-2 / CD200 and their uses
JP5368110B2 (en) 2006-01-20 2013-12-18 ジェネンテック, インコーポレイテッド Anti-ephrin B2 antibody and method of use thereof
TW200744634A (en) 2006-02-21 2007-12-16 Wyeth Corp Methods of using antibodies against human IL-22
TWI417301B (en) 2006-02-21 2013-12-01 Wyeth Corp Antibodies against human il-22 and uses therefor
US8389688B2 (en) 2006-03-06 2013-03-05 Aeres Biomedical, Ltd. Humanized anti-CD22 antibodies and their use in treatment of oncology, transplantation and autoimmune disease
AR059851A1 (en) 2006-03-16 2008-04-30 Genentech Inc Egfl7 antibodies and methods of use
CN103351425B (en) 2006-04-10 2016-01-20 健泰科生物技术公司 Disheveled pdz modulators
US7786270B2 (en) 2006-05-26 2010-08-31 Macrogenics, Inc. Humanized FcγRIIB-specific antibodies and methods of use thereof
ES2543475T3 (en) 2006-05-30 2015-08-19 Genentech, Inc. Anti-CD22 antibodies, their immunoconjugates and their uses
AU2007319672B2 (en) 2006-06-06 2011-06-30 Genentech, Inc. Anti-DLL4 antibodies and methods using same
EP2032159B1 (en) 2006-06-26 2015-01-07 MacroGenics, Inc. Combination of fcgammariib antibodies and cd20-specific antibodies and methods of use thereof
SI2029173T1 (en) 2006-06-26 2016-12-30 Macrogenics, Inc. Fc riib-specific antibodies and methods of use thereof
SI2059536T1 (en) 2006-08-14 2014-06-30 Xencor, Inc. Optimized antibodies that target cd19
JP2010502220A (en) 2006-09-05 2010-01-28 ツィンマーマン デボラ エル. Antibodies against bone morphogenetic proteins and their receptors and methods of use thereof
DK2066349T3 (en) 2006-09-08 2012-07-09 Medimmune Llc Humanized anti-cd19 antibodies and use thereof in treatment of tumors, transplantation and autoimmune diseases
CA2660795C (en) 2006-09-18 2014-11-18 Xencor, Inc. Optimized antibodies that target hm1.24
CA2665239A1 (en) 2006-10-02 2008-05-22 Medarex, Inc. Human antibodies that bind cxcr4 and uses thereof
AU2007319604B2 (en) 2006-10-19 2011-03-24 Csl Limited High affinity antibody antagonists of interleukin-13 receptor alpha 1
CA2666682C (en) 2006-10-19 2014-07-08 Merck & Co., Inc. Anti-il-13r.alpha.1 antibodies and their uses thereof
PL2502938T3 (en) 2006-10-27 2015-07-31 Genentech Inc Antibodies and immunoconjugates and uses therefor
US8618248B2 (en) 2006-10-31 2013-12-31 President And Fellows Of Harvard College Phosphopeptide compositions and anti-phosphopeptide antibody compositions and methods of detecting phosphorylated peptides
BRPI0717964A2 (en) 2006-11-02 2013-12-17 Acceleron Pharma Inc Alk1 binder receiver and antagonists and uses of the same.
AR063840A1 (en) 2006-11-15 2009-02-25 Medarex Inc Human monoclonal antibodies to BTLA, and methods of use
CN103172743B (en) 2006-12-01 2015-04-08 梅达雷克斯有限责任公司 Human Antibodies That Bind Cd22 And Uses Thereof
US8652466B2 (en) 2006-12-08 2014-02-18 Macrogenics, Inc. Methods for the treatment of disease using immunoglobulins having Fc regions with altered affinities for FcγRactivating and FcγRinhibiting
CL2007003622A1 (en) 2006-12-13 2009-08-07 Medarex Inc Human monoclonal antibody anti-CD19; composition comprising; and method of inhibiting the growth of tumor cells.
JP2010513306A (en) 2006-12-14 2010-04-30 メダレックス インコーポレーティッド Human antibodies that bind to CD70 and uses thereof
KR20090114443A (en) 2007-02-09 2009-11-03 제넨테크, 인크. Anti-Robo4 Antibodies and Uses Therefor
CA2681530C (en) 2007-03-22 2017-03-28 Biogen Idec Ma Inc. Binding proteins, including antibodies, antibody derivatives and antibody fragments, that specifically bind cd154
US7960139B2 (en) 2007-03-23 2011-06-14 Academia Sinica Alkynyl sugar analogs for the labeling and visualization of glycoconjugates in cells
HUE039385T2 (en) 2007-04-12 2018-12-28 Brigham & Womens Hospital Inc Targeting ABCB5 for cancer therapy
EP2703011A3 (en) 2007-05-07 2014-03-26 MedImmune, LLC Anti-icos antibodies and their use in treatment of oncology, transplantation and autoimmune disease
EP1997830A1 (en) 2007-06-01 2008-12-03 AIMM Therapeutics B.V. RSV specific binding molecules and means for producing them
PE20090321A1 (en) 2007-06-04 2009-04-20 Genentech Inc Anti-notch1 nrr, preparation method and pharmaceutical composition
CA2688434A1 (en) 2007-06-06 2008-12-11 Domantis Limited Polypeptides, antibody variable domains and antagonists
JP2010535032A (en) 2007-07-31 2010-11-18 メディミューン,エルエルシー Multispecific epitope binding proteins and uses thereof
CN102083861B (en) 2007-08-13 2016-04-13 瓦斯基因治疗公司 Use the cancer therapy in conjunction with the humanized antibody of EphB4
WO2009032845A2 (en) 2007-09-04 2009-03-12 Compugen, Ltd. Polypeptides and polynucleotides, and uses thereof as a drug target for producing drugs and biologics
TWI489993B (en) 2007-10-12 2015-07-01 Novartis Ag Compositions and methods of use for antibodies against sclerostin
CN101951954A (en) 2007-11-02 2011-01-19 诺瓦提斯公司 Molecules and methods for modulating low-density-lipoprotein receptor-related protein 6 (LRP6)
CN108815508A (en) 2007-11-07 2018-11-16 健泰科生物技术公司 For treating the composition and method of microbial conditions
TWI580694B (en) 2007-11-30 2017-05-01 建南德克公司 Anti-vegf antibodies
EP2222706B2 (en) 2007-12-14 2016-08-10 Novo Nordisk A/S Antibodies against human nkg2d and uses thereof
US8795667B2 (en) 2007-12-19 2014-08-05 Macrogenics, Inc. Compositions for the prevention and treatment of smallpox
US8092804B2 (en) 2007-12-21 2012-01-10 Medimmune Limited Binding members for interleukin-4 receptor alpha (IL-4Rα)-173
EP3211010A1 (en) 2007-12-21 2017-08-30 Medimmune Limited Binding members for interleukin-4 receptor alpha (il-4r) - 173
KR101597842B1 (en) 2008-01-11 2016-02-25 가부시키가이샤 진 테크노 사이언스 -9 humanized anti-9 integrin antibodies and the uses thereof
CN101970006B (en) 2008-02-05 2014-08-06 百时美施贵宝公司 Alpha 5 - beta 1 antibodies and their uses
PL2250279T3 (en) * 2008-02-08 2016-11-30 Anti-ifnar1 antibodies with reduced fc ligand affinity
DK2247304T3 (en) 2008-04-02 2016-09-26 Macrogenics Inc Her2 / neu-specific antibodies and methods of use thereof
ES2589912T3 (en) 2008-04-02 2016-11-17 Macrogenics, Inc. Specific antibodies for the BCR complex and procedures for their use
CN104530233B (en) 2008-04-24 2018-01-30 株式会社遗传科技 The amino acid sequence RGD of extracellular matrix protein Humanized antibody specific and its application
CN105963695A (en) 2008-05-02 2016-09-28 阿塞勒隆制药公司 Methods and compositions based on ALK1 antagonists for modulating angiogenesis and pericyte coverage
DK2318832T3 (en) 2008-07-15 2014-01-20 Academia Sinica Glycan arrays on PTFE-like aluminum coated slides and related methods
US9182406B2 (en) 2008-08-04 2015-11-10 Biodesy, Inc. Nonlinear optical detection of molecules comprising an unnatural amino acid possessing a hyperpolarizability
MY159396A (en) 2008-08-05 2016-12-30 Novartis Ag Compositions and methods for antibodies targeting complement protein c5
AR072999A1 (en) 2008-08-11 2010-10-06 Medarex Inc human antibodies that bind to the gene 3 of lymphocyte activation (LAG-3) and uses these
RU2581962C2 (en) 2008-09-19 2016-04-20 Медиммун Ллк Targeted binding agents against dll4 and application thereof
US8298533B2 (en) 2008-11-07 2012-10-30 Medimmune Limited Antibodies to IL-1R1
CA2743469C (en) 2008-11-12 2019-01-15 Medimmune, Llc Antibody formulation
SG194383A1 (en) 2008-12-05 2013-11-29 Glaxo Group Ltd Methods for selecting protease resistant polypeptides
EP2373690B1 (en) 2008-12-08 2015-02-11 Compugen Ltd. Antibodies specific for tmem154
EP2373689A1 (en) 2008-12-12 2011-10-12 MedImmune, LLC Crystals and structure of a human igg fc variant with enhanced fcrn binding
CA2748158A1 (en) 2008-12-23 2010-07-01 Astrazeneca Ab Targeted binding agents directed to .alpha.5.beta.1 and uses thereof
AU2010215479B2 (en) 2009-02-19 2015-01-22 Glaxo Group Limited Improved anti-TNFR1 polypeptides, antibody variable domains & antagonists
WO2010095031A2 (en) 2009-02-23 2010-08-26 Glenmark Pharmaceuticals S.A. Humanized antibodies that bind to cd19 and their uses
UA102891C2 (en) 2009-03-05 2013-08-27 Медарекс, Інк. Fully human antibodies specific to cadm1
ES2572728T3 (en) 2009-03-20 2016-06-02 F. Hoffmann-La Roche Ag Bispecific anti-HER antibodies
WO2010111367A1 (en) 2009-03-25 2010-09-30 Genentech, Inc. Anti-fgfr3 antibodies and methods using same
CA2753988C (en) 2009-03-25 2017-04-25 Genentech, Inc. Novel anti-.alpha.5.beta. integrin antibodies and uses thereof
EP2424894A1 (en) 2009-04-27 2012-03-07 Novartis AG Composition and methods of use for therapeutic antibodies specific for the il-12 receptore betal subunit
PE20121397A1 (en) 2009-04-20 2012-10-23 Oxford Biotherapeutics Ltd antibodies specific for cadherin-17
US9062116B2 (en) 2009-04-23 2015-06-23 Infinity Pharmaceuticals, Inc. Anti-fatty acid amide hydrolase-2 antibodies and uses thereof
CA2993053A1 (en) 2009-04-27 2010-11-04 Novartis Ag Antagonistic activin receptor iib (actriib) antibodies for increasing muscle growth
KR20160005143A (en) 2009-05-13 2016-01-13 젠자임 코포레이션 Anti-human cd52 immunoglobulins
EP2429574B1 (en) 2009-05-15 2015-05-06 University Health Network Compositions and methods for treating hematologic cancers targeting the sirp - cd47 interaction
AU2010261364B2 (en) 2009-06-18 2015-05-07 Pfizer Inc. Anti Notch-1 antibodies
CA2768460A1 (en) 2009-07-16 2011-01-20 Glaxo Group Limited Antagonists, uses & methods for partially inhibiting tnfr1
TW201106972A (en) 2009-07-27 2011-03-01 Genentech Inc Combination treatments
EP2459594A1 (en) 2009-07-31 2012-06-06 N.V. Organon Fully human antibodies to btla
WO2011021146A1 (en) 2009-08-20 2011-02-24 Pfizer Inc. Osteopontin antibodies
WO2011029823A1 (en) 2009-09-09 2011-03-17 Novartis Ag Monoclonal antibody reactive with cd63 when expressed at the surface of degranulated mast cells
US8568726B2 (en) 2009-10-06 2013-10-29 Medimmune Limited RSV specific binding molecule
JP5898082B2 (en) 2009-10-07 2016-04-06 マクロジェニクス,インコーポレーテッド Fc region-containing polypeptide exhibiting improved effector function by changing the degree of fucosylation and use thereof
US20120231004A1 (en) 2009-10-13 2012-09-13 Oxford Biotherapeutic Ltd. Antibodies
EP2491058A1 (en) 2009-10-19 2012-08-29 F.Hoffmann-La Roche Ag Modulators of hepatocyte growth factor activator
CN102648211B (en) 2009-10-22 2015-04-01 霍夫曼-拉罗奇有限公司 Anti-HEPSIN antibodies and methods using same
GEP20166504B (en) 2009-10-23 2016-06-27 Millennium Pharm Inc Anti-gcc antibody molecules and related compositions and methods
WO2011056494A1 (en) 2009-10-26 2011-05-12 Genentech, Inc. Activin receptor-like kinase-1 antagonist and vegfr3 antagonist combinations
WO2011056497A1 (en) 2009-10-26 2011-05-12 Genentech, Inc. Activin receptor type iib compositions and methods of use
WO2011056502A1 (en) 2009-10-26 2011-05-12 Genentech, Inc. Bone morphogenetic protein receptor type ii compositions and methods of use
ES2552177T3 (en) 2009-10-27 2015-11-26 Glaxo Group Limited Stable anti-TNFR1 polypeptides, variable domains of antibodies and antagonists
RU2569109C2 (en) 2009-10-30 2015-11-20 Эйсай Ар Энд Ди Менеджмент Ко., Лтд. Compositions and methods for treating inflammatory diseases
JP6077856B2 (en) 2009-11-04 2017-02-08 メルク・シャープ・アンド・ドーム・コーポレーションMerck Sharp & Dohme Corp. Engineered anti-TSLP antibody This application is filed in US provisional application 61 / 297,008 (filed January 21, 2010) and US provisional application 61 / 258,051 (filed November 4, 2009). ), Each of which is incorporated herein by reference in its entirety.
EP2496601B1 (en) 2009-11-05 2017-06-07 F.Hoffmann-La Roche Ag Methods and composition for secretion of heterologous polypeptides
MX359551B (en) 2009-11-24 2018-10-02 Medimmune Ltd Targeted binding agents against b7-h1.
EP2507265B1 (en) 2009-12-01 2016-05-11 Compugen Ltd. Antibody specific for heparanase splice variant T5 and its use.
RU2012127383A (en) 2009-12-02 2014-01-10 Акселерон Фарма Инк. Compositions and methods for increasing the half time of fc-filled proteins in serum
US10087236B2 (en) 2009-12-02 2018-10-02 Academia Sinica Methods for modifying human antibodies by glycan engineering
EP2509626B1 (en) 2009-12-11 2016-02-10 F.Hoffmann-La Roche Ag Anti-vegf-c antibodies and methods using same
EP2516458A1 (en) 2009-12-22 2012-10-31 Novartis AG Tetravalent cd47-antibody constant region fusion protein for use in therapy
MX2012007379A (en) 2009-12-23 2012-08-31 Genentech Inc Anti-bv8 antibodies and uses thereof.
HUE028629T2 (en) * 2009-12-23 2016-12-28 Synimmune Gmbh Anti-flt3 antibodies and methods of using the same
RU2012134369A (en) 2010-01-11 2014-02-20 Алексион Фармасьютикалз, Инк Biomarkers of immunomodulating effects in people exposed to antimetal treatment against cd200
WO2011091078A2 (en) 2010-01-19 2011-07-28 Xencor, Inc. Antibody fc variants with enhanced complement activity
AR080154A1 (en) 2010-02-10 2012-03-14 Immunogen Inc CD20 antibodies and their use
CA2789125A1 (en) 2010-02-10 2011-08-18 Novartis Ag Methods and compounds for muscle growth
US20110200595A1 (en) 2010-02-18 2011-08-18 Roche Glycart TREATMENT WITH A HUMANIZED IgG CLASS ANTI EGFR ANTIBODY AND AN ANTIBODY AGAINST INSULIN LIKE GROWTH FACTOR 1 RECEPTOR
JP5981853B2 (en) 2010-02-18 2016-08-31 ジェネンテック, インコーポレイテッド Neuregulin antagonists and their use in the treatment of cancer
AR080301A1 (en) 2010-02-24 2012-03-28 Immunogen Inc Antibodies and immunoconjugates of folate receptor 1 and its uses
US8802091B2 (en) 2010-03-04 2014-08-12 Macrogenics, Inc. Antibodies reactive with B7-H3 and uses thereof
PT2542256T (en) 2010-03-04 2019-09-05 Macrogenics Inc Antibodies reactive with b7-h3, immunologically active fragments thereof and uses thereof
KR101899835B1 (en) 2010-03-24 2018-09-19 제넨테크, 인크. Anti-lrp6 antibodies
WO2011130332A1 (en) 2010-04-12 2011-10-20 Academia Sinica Glycan arrays for high throughput screening of viruses
NZ603226A (en) 2010-04-30 2015-02-27 Alexion Pharma Inc Anti-c5a antibodies and methods for using the antibodies
US9290573B2 (en) 2010-05-06 2016-03-22 Novartis Ag Therapeutic low density lipoprotein-related protein 6 (LRP6) multivalent antibodies
JP2013527762A (en) 2010-05-06 2013-07-04 ノバルティス アーゲー Therapeutic low density lipoprotein related protein 6 (LRP6) antibody compositions and methods of use
WO2011147834A1 (en) 2010-05-26 2011-12-01 Roche Glycart Ag Antibodies against cd19 and uses thereof
SG185430A1 (en) 2010-06-03 2012-12-28 Genentech Inc Immuno-pet imaging of antibodies and immunoconjugates and uses therefor
TW201204388A (en) 2010-06-18 2012-02-01 Genentech Inc Anti-Axl antibodies and methods of use
AU2011270959A1 (en) 2010-06-22 2013-01-10 Musc Foundation For Research Development Antibodies to the C3d fragment of complement component 3
WO2011161119A1 (en) 2010-06-22 2011-12-29 F. Hoffmann-La Roche Ag Antibodies against insulin-like growth factor i receptor and uses thereof
WO2011161189A1 (en) 2010-06-24 2011-12-29 F. Hoffmann-La Roche Ag Anti-hepsin antibodies and methods of use
WO2012006503A1 (en) 2010-07-09 2012-01-12 Genentech, Inc. Anti-neuropilin antibodies and methods of use
WO2012010582A1 (en) 2010-07-21 2012-01-26 Roche Glycart Ag Anti-cxcr5 antibodies and methods of use
AU2011286024B2 (en) 2010-08-02 2014-08-07 Macrogenics, Inc. Covalent diabodies and uses thereof
CA2806855A1 (en) 2010-08-03 2012-02-09 F. Hoffmann - La Roche Ag Chronic lymphocytic leukemia (cll) biomarkers
EP2600898A1 (en) 2010-08-05 2013-06-12 F.Hoffmann-La Roche Ag Anti-mhc antibody anti-viral cytokine fusion protein
KR101653030B1 (en) 2010-08-13 2016-08-31 로슈 글리카트 아게 Anti-tenascin-c a2 antibodies and methods of use
HUE036077T2 (en) 2010-08-13 2018-06-28 Roche Glycart Ag Anti-fap antibodies and methods of use
CA2808154A1 (en) 2010-08-13 2012-02-16 Medimmmune Limited Monomeric polypeptides comprising variant fc regions and methods of use
WO2012022734A2 (en) 2010-08-16 2012-02-23 Medimmune Limited Anti-icam-1 antibodies and methods of use
AU2011290672B2 (en) 2010-08-20 2015-07-09 Novartis Ag Antibodies for epidermal growth factor receptor 3 (HER3)
WO2012025536A1 (en) 2010-08-25 2012-03-01 F. Hoffmann-La Roche Ag Antibodies against il-18r1 and uses thereof
CA2808236A1 (en) 2010-08-31 2012-03-08 Genentech, Inc. Biomarkers and methods of treatment
EP2616100B1 (en) 2010-09-17 2016-08-31 Compugen Ltd. Compositions and methods for treatment of drug resistant multiple myeloma
WO2012045703A1 (en) 2010-10-05 2012-04-12 Novartis Ag Anti-il12rbeta1 antibodies and their use in treating autoimmune and inflammatory disorders
JP5974012B2 (en) 2010-10-05 2016-08-23 ジェネンテック, インコーポレイテッド Mutant smoothened and method of using the same
EP3176184A1 (en) 2010-11-10 2017-06-07 F. Hoffmann-La Roche AG Methods and compositions for neural disease immunotherapy
CA2818548A1 (en) 2010-11-19 2012-05-24 Toshio Imai Neutralizing anti-ccl20 antibodies
CA2818635A1 (en) 2010-12-06 2012-06-14 National Reseach Council Of Canada Antibodies selective for cells presenting erbb2 at high density
BR112013015122A2 (en) 2010-12-15 2017-05-30 Wyeth Llc anti-notch1 antibodies
TWI666447B (en) 2010-12-16 2019-07-21 建南德克公司 Diagnosis and treatments relating to th2 inhibition
TWI477513B (en) 2010-12-20 2015-03-21 Genentech Inc Anti-mesothelin antibodies and immunoconjugates
KR20130118925A (en) 2010-12-22 2013-10-30 제넨테크, 인크. Anti-pcsk9 antibodies and methods of use
WO2012092539A2 (en) 2010-12-31 2012-07-05 Takeda Pharmaceutical Company Limited Antibodies to dll4 and uses thereof
AU2012211014A1 (en) 2011-01-24 2013-05-02 National Research Council Of Canada Antibodies selective for cells presenting EGFR at high density
AR085141A1 (en) 2011-02-03 2013-09-11 Alexion Pharma Inc A method for prolonging survival of a kidney allograft, the use of an anti-CD200 to prolong allograft survival
GB2503604A (en) 2011-03-21 2014-01-01 Biodesy Llc Classification of kinase inhibitors using nonlinear optical techniques
PL2691417T3 (en) 2011-03-29 2019-01-31 Roche Glycart Ag Antibody fc variants
RS56916B1 (en) 2011-04-01 2018-05-31 Immunogen Inc Methods for increasing efficacy of folr1 cancer therapy
RU2013143358A (en) 2011-04-07 2015-05-20 Дженентек, Инк. Anti-fgfr4 antibodies and ways of their application
US9469676B2 (en) 2011-04-13 2016-10-18 Bristol-Myers Squibb Company Fc fusion proteins comprising novel linkers or arrangements
RU2016147206A (en) 2011-04-15 2018-10-19 Компуджен Лтд. Polypeptides and polynucleotides and their use for the treatment of immunological disorders and cancer
DK2699590T3 (en) 2011-04-20 2019-05-06 Acceleron Pharma Inc Endoglin polypeptides and applications thereof
WO2012146630A1 (en) 2011-04-29 2012-11-01 F. Hoffmann-La Roche Ag N-terminal acylated polypeptides, methods for their production and uses thereof
PE20141175A1 (en) 2011-05-02 2014-09-25 Millennium Pharm Inc Formulation anti-alfa47
CA3051418A1 (en) 2011-05-02 2012-11-08 Millennium Pharmaceuticals, Inc. Formulation for anti-.alpha.4.beta.7 antibody
RU2638806C2 (en) 2011-05-12 2017-12-15 Дженентек, Инк. Lc-ms/ms method for multiple reactions monitoring to identify therapeutic antibodies in animal species using framework signature peptides
US9346883B2 (en) 2011-05-13 2016-05-24 Institut National De La Sante Et De La Recherche Medicale (Inserm) Antibodies against HER3
US9085626B2 (en) 2011-05-16 2015-07-21 Genentech, Inc. FGFR1 agonists and methods of use
EP2714079B2 (en) 2011-05-21 2019-08-28 MacroGenics, Inc. Deimmunized serum-binding domains and their use for extending serum half-life
CA2837169A1 (en) 2011-05-24 2012-11-29 Zyngenia, Inc. Multivalent and monovalent multispecific complexes and their uses
WO2012172495A1 (en) 2011-06-14 2012-12-20 Novartis Ag Compositions and methods for antibodies targeting tem8
US8623666B2 (en) 2011-06-15 2014-01-07 Hoffmann-La Roche Inc. Method for detecting erythropoietin (EPO) receptor using anti-human EPO receptor antibodies
EA201490020A1 (en) 2011-06-16 2014-04-30 Новартис Аг Soluble proteins for use as therapeutic tools
JP6120833B2 (en) 2011-06-22 2017-04-26 インサーム(インスティテュ ナシオナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシェ メディカル)Inserm(Institut National Dela Sante Et De La Recherche Medicale) Anti-Axl antibody and use thereof
CA2839508A1 (en) 2011-06-22 2012-12-27 Inserm (Institut National De La Sante Et De La Recherche Medicale) Anti-axl antibodies and uses thereof
CN103649125A (en) 2011-06-22 2014-03-19 霍夫曼-拉罗奇有限公司 Removal of target cells by circulating virus-specific cytotoxic t-cells using MHC class I comprising complexes
NZ618503A (en) 2011-06-28 2016-03-31 Oxford Biotherapeutics Ltd Antibodies to adp-ribosyl cyclase 2
TW201306866A (en) 2011-06-30 2013-02-16 Genentech Inc Anti-c-met antibody formulations
CA2836855A1 (en) 2011-06-30 2013-01-03 Compugen Ltd. Polypeptides and uses thereof for treatment of autoimmune disorders and infection
JP6472999B2 (en) 2011-07-01 2019-02-20 ノバルティス アーゲー Methods for treating metabolic disorders
CN103717263B (en) 2011-07-11 2018-01-12 格兰马克药品股份有限公司 Antibody with reference to OX40 and application thereof
EP2731970B1 (en) 2011-07-15 2018-11-28 MorphoSys AG Antibodies that are cross-reactive for macrophage migration inhibitory factor (mif) and d-dopachrome tautomerase (d-dt)
CA2842375A1 (en) 2011-08-17 2013-02-21 Erica Jackson Neuregulin antibodies and uses thereof
RU2014109038A (en) 2011-08-23 2015-09-27 Рош Гликарт Аг Antibodies to chondroitinsulfate proteoglycan melanoma
MX2014003094A (en) 2011-09-15 2014-04-25 Genentech Inc Methods of promoting differentiation.
EP2758055A1 (en) 2011-09-19 2014-07-30 F.Hoffmann-La Roche Ag Combination treatments comprising c-met antagonists and b-raf antagonists
AU2012319150B2 (en) 2011-10-05 2017-08-17 Genentech, Inc. Methods of treating liver conditions using Notch2 antagonists
US8623821B2 (en) 2011-10-14 2014-01-07 Genentech, Inc. Zymogen activators
CN108373506A (en) 2011-10-14 2018-08-07 霍夫曼-拉罗奇有限公司 Anti- HtrA1 antibody and application method
CN104080471B (en) 2011-10-14 2018-08-10 诺华股份有限公司 Antibody and method for Wnt approach relevant diseases
KR20140084164A (en) 2011-10-15 2014-07-04 제넨테크, 인크. Scd1 antagonists for treating cancer
WO2013059531A1 (en) 2011-10-20 2013-04-25 Genentech, Inc. Anti-gcgr antibodies and uses thereof
WO2013063001A1 (en) 2011-10-28 2013-05-02 Genentech, Inc. Therapeutic combinations and methods of treating melanoma
EP2776061B1 (en) 2011-11-07 2019-08-14 MedImmune, LLC Multispecific and multivalent binding proteins and uses thereof
BR112014012005A2 (en) 2011-11-21 2017-12-19 Genentech Inc COMPOSITIONS, METHODS, PHARMACEUTICAL FORMULATION and ARTICLE
UY34487A (en) 2011-12-05 2013-07-31 Novartis Ag Receptor antibodies to epidermal growth factor 3 (HER3)
MX2014006733A (en) 2011-12-05 2015-05-12 Novartis Ag Antibodies for epidermal growth factor receptor 3 (her3) directed to domain ii of her3.
WO2013083497A1 (en) 2011-12-06 2013-06-13 F. Hoffmann-La Roche Ag Antibody formulation
RU2685867C2 (en) 2011-12-15 2019-04-23 Алтернатив Инновейтив Текнолоджиз Ллц Hybrid proteins and protein conjugates based on heat shock protein-70 (hsp70) and methods for use thereof (versions)
JP6231493B2 (en) 2011-12-21 2017-11-15 ノバルティス アーゲー Compositions and methods for antibodies targeting factor P
AR089434A1 (en) 2011-12-23 2014-08-20 Genentech Inc Process for preparing formulations with high protein concentration
WO2013106489A1 (en) 2012-01-09 2013-07-18 The Scripps Research Institute Humanized antibodies with ultralong cdr3s
JP2015504896A (en) 2012-01-09 2015-02-16 ザ・スクリップス・リサーチ・インスティテュート Ultralong complementarity determining region and use thereof
SG10201601747XA (en) 2012-01-18 2016-04-28 Genentech Inc Anti-LRP5 Antibodies And Methods Of Use
WO2013109856A2 (en) 2012-01-18 2013-07-25 Genentech, Inc. Methods of using fgf19 modulators
CN104185681A (en) 2012-02-01 2014-12-03 卡姆普根有限公司 C10RF32 antibodies, and uses thereof for treatment of cancer
CN104583776B (en) 2012-04-25 2016-09-07 比奥德赛公司 For the method detecting the allosteric modulators of protein
US20130209473A1 (en) 2012-02-11 2013-08-15 Genentech, Inc. R-spondin translocations and methods using the same
RU2624128C2 (en) 2012-02-15 2017-06-30 Ф. Хоффманн-Ля Рош Аг AFFINITY CHROMATOGRAPHY WITH APPLICATION OF Fc-RECEPTORS
CN104254541A (en) 2012-03-16 2014-12-31 弗·哈夫曼-拉罗切有限公司 Engineered conformationally-stabilized proteins
US9139863B2 (en) 2012-03-16 2015-09-22 Genentech, Inc. Engineered conformationally-stabilized proteins
CN104220457A (en) 2012-03-27 2014-12-17 霍夫曼-拉罗奇有限公司 Diagnosis and treatments relating to her3 inhibitors
AR090549A1 (en) 2012-03-30 2014-11-19 Genentech Inc Antibodies and immunoconjugates LGR5
US9657091B2 (en) 2012-04-05 2017-05-23 Ac Immune S.A. Humanized tau antibody
US10130714B2 (en) 2012-04-14 2018-11-20 Academia Sinica Enhanced anti-influenza agents conjugated with anti-inflammatory activity
US9156915B2 (en) 2012-04-26 2015-10-13 Thomas Jefferson University Anti-GCC antibody molecules
MX2014012889A (en) 2012-05-01 2014-11-14 Genentech Inc Anti-pmel17 antibodies and immunoconjugates.
WO2013170191A1 (en) 2012-05-11 2013-11-14 Genentech, Inc. Methods of using antagonists of nad biosynthesis from nicotinamide
RU2625771C2 (en) 2012-05-23 2017-07-18 Дженентек, Инк. Therapeutics selection method
CA2873998A1 (en) 2012-06-04 2013-12-12 Irm Llc Site-specific labeling methods and molecules produced thereby
CA2875703A1 (en) 2012-06-08 2013-12-12 Glenmark Pharmaceuticals S.A. Anti-trka antibodies with enhanced inhibitory properties and derivatives thereof
CA2875096A1 (en) 2012-06-15 2013-12-19 Genentech, Inc. Anti-pcsk9 antibodies, formulations, dosing, and methods of use
UY34887A (en) 2012-07-02 2013-12-31 Bristol Myers Squibb Company Una Corporacion Del Estado De Delaware Optimization of antibodies that bind to the gene of T cell activation 3 (LAG-3) and their uses
EP3339328A1 (en) 2012-07-04 2018-06-27 F. Hoffmann-La Roche AG Anti-biotin antibodies and methods of use
ES2600154T3 (en) 2012-07-04 2017-02-07 F. Hoffmann-La Roche Ag Anti-theophylline antibodies and methods of use
EP2869848B1 (en) 2012-07-04 2016-09-21 F.Hoffmann-La Roche Ag Covalently linked antigen-antibody conjugates
KR20150030693A (en) 2012-07-05 2015-03-20 제넨테크, 인크. Expression and secretion system
SG11201500096YA (en) 2012-07-09 2015-02-27 Genentech Inc Immunoconjugates comprising anti - cd79b antibodies
CA2873884A1 (en) 2012-07-09 2014-01-16 Genentech, Inc. Immunoconjugates comprising anti-cd79b antibodies
BR112015000441A2 (en) 2012-07-09 2017-12-19 Genentech Inc Immunoconjugates, Pharmaceutical Formulation and Treatment Method and Method for Inhibiting Proliferation of a CD22 Positive Cell
BR112015000439A2 (en) 2012-07-09 2017-12-19 Genentech Inc immunoconjugate, pharmaceutical formulation and methods of treating an individual and inhibiting proliferation
CA2874554A1 (en) 2012-07-13 2014-01-16 Roche Glycart Ag Bispecific anti-vegf/anti-ang-2 antibodies and their use in the treatment of ocular vascular diseases
ES2673847T3 (en) 2012-07-25 2018-06-26 Celldex Therapeutics, Inc. Anti KIT antibodies and uses thereof
WO2014020056A1 (en) 2012-08-02 2014-02-06 F. Hoffmann-La Roche Ag METHOD FOR PRODUCING SOLUBLE FcR AS Fc-FUSION WITH INERT IMMUNOGLOBULIN Fc-REGION AND USES THEREOF
AU2013306098A1 (en) 2012-08-18 2015-02-12 Academia Sinica Cell-permeable probes for identification and imaging of sialidases
NZ726258A (en) 2012-08-31 2019-07-26 Immunogen Inc Antibodies and uses thereof to detect folate receptor 1
US9376489B2 (en) 2012-09-07 2016-06-28 Novartis Ag IL-18 binding molecules
KR20150064205A (en) 2012-11-08 2015-06-10 에프. 호프만-라 로슈 아게 Her3 antigen binding proteins binding to the beta-hairpin of her3
SG11201503734UA (en) 2012-11-13 2015-06-29 Genentech Inc Anti-hemagglutinin antibodies and methods of use
EP2733153A1 (en) 2012-11-15 2014-05-21 INSERM (Institut National de la Santé et de la Recherche Medicale) Methods for the preparation of immunoconjugates and uses thereof
WO2014084859A1 (en) 2012-11-30 2014-06-05 Novartis Ag Molecules and methods for modulating tmem16a activities
US9365646B2 (en) 2012-12-05 2016-06-14 Novartis Ag Compositions and methods for antibodies targeting EPO
CA2893375A1 (en) 2012-12-10 2014-06-19 Biogen Ma Inc. Anti-blood dendritic cell antigen 2 antibodies and uses thereof
EP2931752B1 (en) 2012-12-17 2019-08-14 Trillium Therapeutics Inc. Treatment of cd47+ disease cells with sirp alpha-fc fusions
MX360155B (en) 2013-01-02 2018-10-24 Glenmark Pharmaceuticals Sa Antibodies that bind to tl1a and their uses.
WO2014107739A1 (en) 2013-01-07 2014-07-10 Eleven Biotherapeutics, Inc. Antibodies against pcsk9
WO2014116749A1 (en) 2013-01-23 2014-07-31 Genentech, Inc. Anti-hcv antibodies and methods of using thereof
EP3161001A2 (en) 2014-06-25 2017-05-03 Novartis AG Antibodies specific for il-17a fused to hyaluronan binding peptide tags
WO2014124258A2 (en) 2013-02-08 2014-08-14 Irm Llc Specific sites for modifying antibodies to make immunoconjugates
SG11201505330QA (en) 2013-02-08 2015-08-28 Novartis Ag Anti-il-17a antibodies and their use in treating autoimmune and inflammatory disorders
EA201591465A1 (en) 2013-02-08 2015-12-30 АйАрЭм ЭлЭлСи Specific plots for modification of antibodies for obtaining immunoconjugates
EP2956468A1 (en) 2013-02-12 2015-12-23 Bristol-Myers Squibb Company Tangential flow filtration based protein refolding methods
ES2645634T3 (en) 2013-02-12 2017-12-07 Bristol-Myers Squibb Company High pH protein refolding methods
MX2015010791A (en) 2013-02-22 2015-11-26 Hoffmann La Roche Methods of treating cancer and preventing drug resistance.
CA2896259A1 (en) 2013-02-26 2014-09-04 Roche Glycart Ag Anti-mcsp antibodies
US9487587B2 (en) 2013-03-05 2016-11-08 Macrogenics, Inc. Bispecific molecules that are immunoreactive with immune effector cells of a companion animal that express an activating receptor and cells that express B7-H3 and uses thereof
MX2015011428A (en) 2013-03-06 2016-02-03 Genentech Inc Methods of treating and preventing cancer drug resistance.
US9498532B2 (en) 2013-03-13 2016-11-22 Novartis Ag Antibody drug conjugates
US9562099B2 (en) 2013-03-14 2017-02-07 Genentech, Inc. Anti-B7-H4 antibodies and immunoconjugates
EP2970479B1 (en) 2013-03-14 2019-04-24 Novartis AG Antibodies against notch 3
AU2014244286B2 (en) 2013-03-14 2018-11-08 Duke University Bispecific molecules that are immunoreactive with immune effector cells that express an activating receptor
CN105307683A (en) 2013-03-14 2016-02-03 基因泰克公司 Methods of treating cancer and preventing cancer drug resistance
PE20151672A1 (en) 2013-03-14 2015-11-27 Genentech Inc Antibodies and immunoconjugates anti-b7-h4
CN105246508A (en) 2013-03-14 2016-01-13 基因泰克公司 Combinations of a mek inhibitor compound with an her3/egfr inhibitor compound and methods of use
WO2014144850A1 (en) 2013-03-15 2014-09-18 Genentech, Inc. Methods of treating cancer and preventing cancer drug resistance
US10035859B2 (en) 2013-03-15 2018-07-31 Biogen Ma Inc. Anti-alpha V beta 6 antibodies and uses thereof
WO2014143739A2 (en) 2013-03-15 2014-09-18 Biogen Idec Ma Inc. Anti-alpha v beta 6 antibodies and uses thereof
CN105451767B (en) 2013-03-15 2019-10-18 泽恩格尼亚股份有限公司 Multivalence and monovalent polyspecific compound and application thereof
ES2701051T3 (en) 2013-03-15 2019-02-20 Novartis Ag Antibody-drug conjugates
TW201511770A (en) 2013-03-15 2015-04-01 Genentech Inc Compositions and methods for diagnosis and treatment of hepatic cancers
CN105142668B (en) 2013-03-15 2018-04-27 达纳-法伯癌症研究院公司 Therapeutic peptide
SG10201701380TA (en) 2013-03-15 2017-04-27 Genentech Inc Biomarkers and methods of treating pd-1 and pd-l1 related conditions
AR095199A1 (en) 2013-03-15 2015-09-30 Genzyme Corp Anti-CD52 antibodies
HUE039291T2 (en) 2013-03-15 2018-12-28 Hoffmann La Roche Il-22 polypeptides and il-22 fc fusion proteins and methods of use
US20160017041A1 (en) 2013-03-15 2016-01-21 Biogen Ma Inc. Treatment and prevention of acute kidney injury using anti-alpha v beta 5 antibodies
JP6568514B2 (en) 2013-03-15 2019-08-28 エーシー イミューン エス.エー. Anti-tau antibodies and methods of use
WO2014144865A2 (en) 2013-03-15 2014-09-18 Genentech, Inc. Anti-crth2 antibodies and methods of use
SG10201800492PA (en) 2013-04-29 2018-03-28 Hoffmann La Roche Human fcrn-binding modified antibodies and methods of use
CA2908653A1 (en) 2013-04-29 2014-11-06 F. Hoffmann-La Roche Ag Fcrn-binding abolished anti-igf-1r antibodies and their use in the treatment of vascular eye diseases
WO2014186877A1 (en) 2013-05-24 2014-11-27 Uger Marni Diane FasR ANTIBODIES FOR DIAGNOSTIC AND THERAPEUTIC USE
AR096601A1 (en) 2013-06-21 2016-01-20 Novartis Ag Antibodies receptor 1 ldl similar oxidized lectin and methods of use
UY35620A (en) 2013-06-21 2015-01-30 Novartis Ag Antibodies receptor 1 ldl similar oxidized lectin and methods of use
EP3013365B1 (en) 2013-06-26 2019-06-05 Academia Sinica Rm2 antigens and use thereof
WO2014210564A1 (en) 2013-06-27 2014-12-31 Academia Sinica Glycan conjugates and use thereof
EP3022224A2 (en) 2013-07-18 2016-05-25 Fabrus, Inc. Antibodies with ultralong complementarity determining regions
AU2014290361B2 (en) 2013-07-18 2019-04-18 Taurus Biosciences, Llc Humanized antibodies with ultralong complementarity determining regions
JP6395834B2 (en) 2013-08-09 2018-09-26 マクロジェニクス,インコーポレーテッド Bispecific monovalent Fc diabody capable of binding to CD32B and CD79b and uses thereof
EP3033358A2 (en) 2013-08-14 2016-06-22 Novartis AG Methods of treating sporadic inclusion body myositis
EP2840091A1 (en) 2013-08-23 2015-02-25 MacroGenics, Inc. Bi-specific diabodies that are capable of binding gpA33 and CD3 and uses thereof
EP2839842A1 (en) 2013-08-23 2015-02-25 MacroGenics, Inc. Bi-specific monovalent diabodies that are capable of binding CD123 and CD3 and uses thereof
KR20160055831A (en) 2013-08-30 2016-05-18 이뮤노젠 아이엔씨 Antibodies and assays for detection of folate receptor 1
CN105682666A (en) 2013-09-06 2016-06-15 中央研究院 Human iNKT cell activation using glycolipids with altered glycosyl groups
EP3044234A4 (en) 2013-09-13 2017-08-09 Beigene, Ltd. Anti-pd1 antibodies and their use as therapeutics and diagnostics
BR112016004450A2 (en) 2013-09-17 2017-10-17 Genentech Inc methods for treating a disease, for increasing the effectiveness of a treatment, for postponing and / or preventing the development of recurrence and / or resistance of a disease, for increasing sensitivity to an inhibitor, for extending the sensitivity period for an inhibitor and for extend response time to an inhibitor
JP6534615B2 (en) 2013-09-27 2019-06-26 中外製薬株式会社 Method for producing polypeptide heteromultimer
CN105814078A (en) 2013-10-11 2016-07-27 豪夫迈·罗氏有限公司 Nsp4 inhibitors and methods of use
RU2016115866A (en) 2013-10-11 2017-11-16 Ф. Хоффманн-Ля Рош Аг Multi-specific antibodies with exchanged domains and same variable domains of easy chain
WO2015057939A1 (en) 2013-10-18 2015-04-23 Biogen Idec Ma Inc. Anti-s1p4 antibodies and uses thereof
US20150147333A1 (en) 2013-10-18 2015-05-28 Genentech, Inc. Anti-rspo antibodies and methods of use
RU2016119425A3 (en) 2013-10-23 2018-05-30
KR20160101909A (en) 2013-11-07 2016-08-26 인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) Neuregulin allosteric anti-her3 antibody
BR112016010065A2 (en) 2013-11-21 2017-12-05 Hoffmann La Roche alpha-synuclein antibodies and methods of use
AU2014360273A1 (en) 2013-12-06 2016-06-02 Dana-Farber Cancer Institute, Inc. Therapeutic peptides
US9546215B2 (en) 2013-12-09 2017-01-17 Allakos Inc. Anti-Siglec-8 antibodies and methods of use thereof
EP3461845A1 (en) 2013-12-13 2019-04-03 Genentech, Inc. Anti-cd33 antibodies and immunoconjugates
BR112016013896A2 (en) 2013-12-17 2017-10-10 Genentech Inc Her2-positive cancer treatment methods using pd-1 axis binding antagonists and anti-her2 antibodies
SG10201800250XA (en) 2013-12-17 2018-02-27 Genentech Inc Anti-cd3 antibodies and methods of use
US20150210772A1 (en) 2013-12-17 2015-07-30 Genentech, Inc. Methods of treating cancer using pd-1 axis binding antagonists and an anti-cd20 antibody
SG11201604979WA (en) 2013-12-17 2016-07-28 Genentech Inc Combination therapy comprising ox40 binding agonists and pd-1 axis binding antagonists
PE20161032A1 (en) 2013-12-20 2016-10-19 F Hoffmann-La Roche Ag Anti-tau (ps422) Humanized and methods of use
AU2014369999A1 (en) 2013-12-24 2016-07-07 The Board Of Regents Of The University Of Texas System FcRn antagonists and methods of use
KR20160105880A (en) 2014-01-03 2016-09-07 에프. 호프만-라 로슈 아게 Covalently linked polypeptide toxin-antibody conjugates
BR112016012666A2 (en) 2014-01-03 2017-09-26 Hoffmann La Roche conjugate, antibodies, pharmaceutical formulation and uses of conjugate
RU2693438C2 (en) 2014-01-03 2019-07-02 Ф. Хоффманн-Ля Рош Аг Bispecific anti-hapten/anti-blood brain barrier receptor antibodies, complexes thereof and their use as blood brain barrier shuttles
CA2932547A1 (en) 2014-01-06 2015-07-09 F. Hoffmann-La Roche Ag Monovalent blood brain barrier shuttle modules
JP2017505767A (en) 2014-01-15 2017-02-23 エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft Fc region variants with altered FcRn binding properties and retained protein A binding properties
WO2015109180A2 (en) 2014-01-16 2015-07-23 Academia Sinica Compositions and methods for treatment and detection of cancers
US10118969B2 (en) 2014-05-27 2018-11-06 Academia Sinica Compositions and methods relating to universal glycoforms for enhanced antibody efficacy
US10150818B2 (en) 2014-01-16 2018-12-11 Academia Sinica Compositions and methods for treatment and detection of cancers
US9975965B2 (en) 2015-01-16 2018-05-22 Academia Sinica Compositions and methods for treatment and detection of cancers
MX2016009515A (en) 2014-01-24 2016-10-26 Genentech Inc Methods of using anti-steap1 antibodies and immunoconjugates.
US20170044232A1 (en) 2014-02-04 2017-02-16 Genentech, Inc. Mutant smoothened and methods of using the same
JP2017507130A (en) 2014-02-08 2017-03-16 ジェネンテック, インコーポレイテッド How to treat Alzheimer's disease
JP2017511793A (en) 2014-02-08 2017-04-27 ジェネンテック, インコーポレイテッド Alzheimer's disease treatment method
TW201902515A (en) 2014-02-12 2019-01-16 美商建南德克公司 Anti-jagged1 antibodies and methods of use
MX2016010729A (en) 2014-02-21 2016-10-26 Genentech Inc Anti-il-13/il-17 bispecific antibodies and uses thereof.
AU2015222757A1 (en) 2014-02-28 2016-09-08 Allakos Inc. Methods and compositions for treating Siglec-8 associated diseases
NZ631007A (en) 2014-03-07 2015-10-30 Alexion Pharma Inc Anti-c5 antibodies having improved pharmacokinetics
WO2015138615A2 (en) 2014-03-12 2015-09-17 Irm Llc Specific sites for modifying antibodies to make immunoconjugates
JP2017510294A (en) 2014-03-14 2017-04-13 ジェネンテック, インコーポレイテッド Methods and compositions for secreting heterologous polypeptides
CN106456728A (en) 2014-03-14 2017-02-22 达纳-法伯癌症研究所公司 Vaccine compositions and methods for restoring NKG2D pathway function against cancers
US20170107294A1 (en) 2014-03-21 2017-04-20 Nordlandssykehuset Hf Anti-cd14 antibodies and uses thereof
MX2016012285A (en) 2014-03-24 2017-01-23 Genentech Inc Cancer treatment with c-met antagonists and correlation of the latter with hgf expression.
TW201605873A (en) 2014-03-27 2016-02-16 中央研究院 Reactive labelling compounds and uses thereof
JP6588461B2 (en) 2014-03-31 2019-10-09 ジェネンテック, インコーポレイテッド Combination therapy comprising an anti-angiogenic agent and an OX40 binding agonist
JP2017514461A (en) 2014-03-31 2017-06-08 ジェネンテック, インコーポレイテッド Anti-OX40 antibody and method of use
EP3134439B1 (en) 2014-04-21 2018-12-26 Millennium Pharmaceuticals, Inc. Anti-psyk antibody molecules and use of same for syk-targeted therapy
TW201622746A (en) 2014-04-24 2016-07-01 諾華公司 Methods of improving or accelerating physical recovery after surgery for hip fracture
WO2015164615A1 (en) 2014-04-24 2015-10-29 University Of Oslo Anti-gluten antibodies and uses thereof
EP3142483A1 (en) 2014-05-05 2017-03-22 Regeneron Pharmaceuticals, Inc. Humanized c5 and c3 animals
WO2015179658A2 (en) 2014-05-22 2015-11-26 Genentech, Inc. Anti-gpc3 antibodies and immunoconjugates
BR112016025040A2 (en) 2014-05-23 2018-02-20 Genentech Inc methods to determine mit biomarker expression, to treat cancer, to identify an individual with cancer, to predict whether an individual with cancer is more or less likely to respond effectively to treatment, to inhibit cell proliferation, and to treat nccrcc in an individual
TW201609137A (en) 2014-05-27 2016-03-16 中央研究院 Anti-HER2 glycoantibodies and uses thereof
KR20170005142A (en) 2014-05-27 2017-01-11 아카데미아 시니카 Compositions and methods relating to universal glycoforms for enhanced antibody efficacy
MX2016015614A (en) 2014-05-28 2017-08-21 Agenus Inc Anti-gitr antibodies and methods of use thereof.
KR101923326B1 (en) 2014-06-06 2018-11-29 브리스톨-마이어스 스큅 컴퍼니 Antibodies against glucocorticoid-induced tumor necrosis factor receptor (gitr) and uses thereof
RU2016148616A (en) 2014-06-11 2018-07-18 Дженентек, Инк. Anti-lgr5 antibodies and their application
JP2017517552A (en) 2014-06-13 2017-06-29 ジェネンテック, インコーポレイテッド Treatment and prevention of anticancer drug resistance
AR100978A1 (en) 2014-06-26 2016-11-16 F Hoffmann-La Roche Ag SHUTTLE BRAIN OF ANTI-Tau Humanized Antibody (pS422) AND USES THEREOF
MX2017000419A (en) 2014-07-11 2017-08-16 Genentech Inc Anti-pd-l1 antibodies and diagnostic uses thereof.
CA2952315A1 (en) 2014-07-11 2016-01-14 Genentech, Inc. Notch pathway inhibition
US8980273B1 (en) 2014-07-15 2015-03-17 Kymab Limited Method of treating atopic dermatitis or asthma using antibody to IL4RA
US8986691B1 (en) 2014-07-15 2015-03-24 Kymab Limited Method of treating atopic dermatitis or asthma using antibody to IL4RA
AU2015292678A1 (en) 2014-07-22 2017-02-16 Cb Therapeutics, Inc. Anti-PD-1 antibodies
WO2016020791A1 (en) 2014-08-05 2016-02-11 Novartis Ag Ckit antibody drug conjugates
AU2015301126A1 (en) 2014-08-05 2017-02-23 Cb Therapeutics, Inc. Anti-PD-L1 antibodies
US9988443B2 (en) 2014-08-07 2018-06-05 Novartis Ag Angiopoetin-like 4 (ANGPTL4) antibodies and methods of use
WO2016020880A2 (en) 2014-08-07 2016-02-11 Novartis Ag Angiopoietin-like 4 antibodies and methods of use
SG11201700254QA (en) 2014-08-12 2017-02-27 Novartis Ag Anti-cdh6 antibody drug conjugates
KR102037197B1 (en) 2014-08-19 2019-10-28 머크 샤프 앤드 돔 코포레이션 Anti-lag3 antibodies and antigen-binding fragments
WO2016028656A1 (en) 2014-08-19 2016-02-25 Merck Sharp & Dohme Corp. Anti-tigit antibodies
US9879042B2 (en) 2014-09-08 2018-01-30 Academia Sinica Human iNKT cell activation using glycolipids
KR20170052600A (en) 2014-09-12 2017-05-12 제넨테크, 인크. Cysteine engineered antibodies and conjugates
US10059768B2 (en) 2014-09-12 2018-08-28 Genentech, Inc. Anti-B7-H4 antibodies and immunoconjugates
JP2017534256A (en) 2014-09-12 2017-11-24 ジェネンテック, インコーポレイテッド ANTI-CLL-1 antibody and immune complex
MX2017003472A (en) 2014-09-17 2017-10-31 Genentech Inc Immunoconjugates comprising anti-her2 antibodies and pyrrolobenzodiazepines.
CR20170138A (en) 2014-10-08 2017-08-21 Novartis Ag Compositions and methods used to increase the immune response and cancer therapy
WO2016061389A2 (en) 2014-10-16 2016-04-21 Genentech, Inc. Anti-alpha-synuclein antibodies and methods of use
KR20170086540A (en) 2014-11-03 2017-07-26 제넨테크, 인크. Assays for detecting t cell immune subsets and methods of use thereof
AU2015342964A1 (en) 2014-11-05 2017-06-15 Genentech, Inc. Methods of producing two chain proteins in bacteria
BR112017008666A2 (en) 2014-11-05 2018-01-30 Genentech Inc anti-fgfr2 / 3 antibodies and methods of use
CN108064308A (en) 2014-11-05 2018-05-22 豪夫迈·罗氏有限公司 The method that dichain proteins are generated in bacterium
WO2016073157A1 (en) 2014-11-06 2016-05-12 Genentech, Inc. Anti-ang2 antibodies and methods of use thereof
EP3215536A1 (en) 2014-11-06 2017-09-13 F. Hoffmann-La Roche AG Combination therapy comprising ox40 binding agonists and tigit inhibitors
EP3552488A1 (en) 2014-11-10 2019-10-16 F. Hoffmann-La Roche AG Animal model for nephropathy and agents for treating the same
WO2016077381A1 (en) 2014-11-10 2016-05-19 Genentech, Inc. Anti-interleukin-33 antibodies and uses thereof
CA2967188A1 (en) 2014-11-14 2016-05-19 Novartis Ag Antibody drug conjugates
CN106999583A (en) 2014-11-17 2017-08-01 豪夫迈·罗氏有限公司 Combination treatment comprising OX40 combinations activator and the axle binding antagonists of PD 1
JP2018505651A (en) 2014-11-19 2018-03-01 ジェネンテック, インコーポレイテッド Antibodies against BACEl and their use for neurological disease immunotherapy
WO2016081643A1 (en) 2014-11-19 2016-05-26 Genentech, Inc. Anti-transferrin receptor antibodies and methods of use
CN107250158A (en) 2014-11-19 2017-10-13 基因泰克公司 Anti-rotation Human Placental Ferritin Receptor/anti-BACE1 multi-specificity antibodies and application method
EA201790986A1 (en) 2014-11-21 2017-10-31 Бристол-Майерс Сквибб Компани Antibodies to cd73 and their applications
US20170327584A1 (en) 2014-11-26 2017-11-16 Millennium Pharmaceuticals, Inc. Vedolizumab for the Treatment of Fistulizing Crohn's Disease
EP3226900A4 (en) 2014-12-05 2018-09-19 Immunext, Inc. Identification of vsig8 as the putative vista receptor and its use thereof to produce vista/vsig8 modulators
SG11201704449VA (en) 2014-12-05 2017-06-29 Genentech Inc ANTI-CD79b ANTIBODIES AND METHODS OF USE
JP2017538415A (en) 2014-12-09 2017-12-28 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル Human monoclonal antibody against AXL
CN107207591A (en) 2014-12-10 2017-09-26 豪夫迈·罗氏有限公司 Blood-brain barrier receptor antibody and application method
UY36449A (en) 2014-12-19 2016-07-29 Novartis Ag Compositions and methods for antibodies directed to BMP6
CA2971542A1 (en) 2014-12-19 2016-06-23 Regenesance B.V. Antibodies that bind human c6 and uses thereof
JP2018511557A (en) 2015-01-22 2018-04-26 中外製薬株式会社 Combination and use of two or more anti-C5 antibodies
KR20170104617A (en) 2015-01-24 2017-09-15 아카데미아 시니카 Novel glycan conjugates and methods for using them
CN107430127A (en) 2015-01-24 2017-12-01 中央研究院 Cancer markers and its application method
BR112017014328A2 (en) 2015-02-05 2018-01-02 Chugai Pharmaceutical Co Ltd antibodies comprising an ion concentration-dependent antigen binding domain, fc region variants, il-8 binding antibodies, methods of producing them and for prolonging or reducing the half-life of an antibody in plasma, pharmaceutical composition, nucleic acid, vector, host cell
EP3259597A2 (en) 2015-02-19 2017-12-27 Compugen Ltd. Pvrig polypeptides and methods of treatment
EP3295951A1 (en) 2015-02-19 2018-03-21 Compugen Ltd. Anti-pvrig antibodies and methods of use
WO2016135041A1 (en) 2015-02-26 2016-09-01 INSERM (Institut National de la Santé et de la Recherche Médicale) Fusion proteins and antibodies comprising thereof for promoting apoptosis
JP2018509413A (en) 2015-03-09 2018-04-05 アルゲン−エックス ビーブイビーエー Methods for reducing serum levels of Fc-containing agents using FcRn antagonists
CN107430117A (en) 2015-03-16 2017-12-01 豪夫迈·罗氏有限公司 Detection and quantitative IL 13 method and the purposes in diagnosing and treating Th2 relevant diseases
WO2016146833A1 (en) 2015-03-19 2016-09-22 F. Hoffmann-La Roche Ag Biomarkers for nad(+)-diphthamide adp ribosyltransferase resistance
CN107106671A (en) 2015-04-03 2017-08-29 优瑞科生物技术公司 Construct of target AFP peptide/MHC complexs and application thereof
CN107969128A (en) 2015-04-17 2018-04-27 高山免疫科学股份有限公司 Immune modulator with adjustable affinity
EP3286315A2 (en) 2015-04-24 2018-02-28 Genentech, Inc. Methods of identifying bacteria comprising binding polypeptides
WO2016179003A1 (en) 2015-05-01 2016-11-10 Genentech, Inc. Masked anti-cd3 antibodies and methods of use
BR112017023849A2 (en) 2015-05-07 2018-07-17 Agenus Inc anti-ox40 antibodies and methods of use
US20180127510A1 (en) 2015-05-22 2018-05-10 INSERM (Institut National de la Santé et de la Recherche Médicale) Human monoclonal antibodies fragments inhibiting both the cath-d catalytic activity and its binding to the lrp1 receptor
US20180237534A1 (en) 2015-05-29 2018-08-23 Bristol-Myers Squibb Company Antibodies against ox40 and uses thereof
KR20180012753A (en) 2015-05-29 2018-02-06 제넨테크, 인크. Treatment and Diagnosis Methods for Cancer
JP2018520658A (en) 2015-05-29 2018-08-02 ジェネンテック, インコーポレイテッド Humanized anti-Ebola virus glycoprotein antibodies and uses thereof
WO2016196679A1 (en) 2015-06-02 2016-12-08 Genentech, Inc. Compositions and methods for using anti-il-34 antibodies to treat neurological diseases
EA201792561A1 (en) 2015-06-05 2018-04-30 Новартис Аг Antibodies aimed on morphogenetic bone 9 protection (bmp9) and methods of their application
RU2017145540A (en) 2015-06-05 2019-07-16 Дженентек, Инк. Antibodies against tau-protein and methods of their application
KR20180025888A (en) 2015-06-08 2018-03-09 제넨테크, 인크. Methods for treating cancer using anti-OX40 antibodies and PD-1 axis-binding antagonists
CN107810011A (en) 2015-06-08 2018-03-16 豪夫迈·罗氏有限公司 Use the method for anti-OX40 antibodies for treating cancer
AR104987A1 (en) 2015-06-15 2017-08-30 Genentech Inc Antibody-drug immunoconjugates linked by linkers nonpeptide
CN107849145A (en) 2015-06-16 2018-03-27 基因泰克公司 Anti-cd 3 antibodies and its application method
JP2018527887A (en) 2015-06-16 2018-09-27 ジェネンテック, インコーポレイテッド Humanized affinity matured antibodies against FcRH5 and methods of use
WO2016205200A1 (en) 2015-06-16 2016-12-22 Genentech, Inc. Anti-cll-1 antibodies and methods of use
MX2017016169A (en) 2015-06-17 2018-08-15 Genentech Inc Anti-her2 antibodies and methods of use.
US20190194315A1 (en) 2015-06-17 2019-06-27 Novartis Ag Antibody drug conjugates
CA2986263A1 (en) 2015-06-17 2016-12-22 Genentech, Inc. Methods of treating locally advanced or metastatic breast cancers using pd-1 axis binding antagonists and taxanes
UY36751A (en) 2015-06-26 2017-01-31 Novartis Ag Xi factor antibodies and methods of use
CA2989936A1 (en) 2015-06-29 2017-01-05 Genentech, Inc. Type ii anti-cd20 antibody for use in organ transplantation
EP3514174A1 (en) 2015-06-29 2019-07-24 Ventana Medical Systems, Inc. Materials and methods for performing histochemical assays for human pro-epiregulin and amphiregulin
AU2016291846A1 (en) 2015-07-13 2018-01-25 Compugen Ltd. Hide1 compositions and methods
CN108350072A (en) 2015-08-03 2018-07-31 诺华股份有限公司 The method for treating FGF21 associated diseases
CN108026180A (en) 2015-08-28 2018-05-11 豪夫迈·罗氏有限公司 Anti- hydroxyl putrescine lysine antibody and application thereof
CN107949573A (en) 2015-09-01 2018-04-20 艾吉纳斯公司 Anti- 1 antibody of PD and its application method
UY36889A (en) 2015-09-09 2017-04-28 Novartis Ag Binding molecules thymic stromal lymphopoietin (TSLP) and methods of using the molecules
US9862760B2 (en) 2015-09-16 2018-01-09 Novartis Ag Polyomavirus neutralizing antibodies
KR20180053319A (en) 2015-09-17 2018-05-21 이뮤노젠 아이엔씨 Therapeutic combinations comprising an anti-FOLR1 immunoconjugate
MX2018003005A (en) 2015-09-18 2018-04-11 Chugai Pharmaceutical Co Ltd Il-8-binding antibodies and uses thereof.
AU2016328357A1 (en) 2015-09-22 2018-03-01 Spring Bioscience Corporation Anti-OX40 antibodies and diagnostic uses thereof
RU2018114723A (en) 2015-09-23 2019-10-23 Дженентек, Инк. Optimized anti-vegf antibodies options
AR106189A1 (en) 2015-10-02 2017-12-20 F Hoffmann-La Roche Ag Bispecific antibodies against human Ab AND human transferrin receptor and methods of use
CN108391422A (en) 2015-10-02 2018-08-10 豪夫迈·罗氏有限公司 Pyrrolobenzodiazepines * antibody-drug conjugates and application method
EP3150636A1 (en) 2015-10-02 2017-04-05 F. Hoffmann-La Roche AG Tetravalent multispecific antibodies
MX2018003630A (en) 2015-10-02 2018-08-01 F Hoffmann ­La Roche Ag Bispecific antibodies specific for pd1 and tim3.
JP2018535662A (en) 2015-10-02 2018-12-06 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト Bispecific antibody to costimulatory TNF receptor
EP3356406A1 (en) 2015-10-02 2018-08-08 H. Hoffnabb-La Roche Ag Bispecific anti-human cd20/human transferrin receptor antibodies and methods of use
US20170247454A1 (en) 2015-10-02 2017-08-31 Hoffmann-La Roche Inc. Anti-pd1 antibodies and methods of use
EP3359568A1 (en) 2015-10-07 2018-08-15 H. Hoffnabb-La Roche Ag Bispecific antibodies with tetravalency for a costimulatory tnf receptor
WO2017066714A1 (en) 2015-10-16 2017-04-20 Compugen Ltd. Anti-vsig1 antibodies and drug conjugates
JP2018537416A (en) 2015-10-16 2018-12-20 ジェネンテック, インコーポレイテッド Constrained disulfide drug conjugate
JP2018533568A (en) 2015-10-20 2018-11-15 ジェネンテック, インコーポレイテッド Calicheamicin-antibody-drug conjugates and methods of use
CA3000048A1 (en) 2015-10-29 2017-05-04 F. Hoffmann-La Roche Ag Anti-variant fc-region antibodies and methods of use
AU2016344070B2 (en) 2015-10-29 2019-11-07 Merck Sharp & Dohme Corp. Antibody neutralizing human respiratory syncytial virus
EP3184547A1 (en) 2015-10-29 2017-06-28 F. Hoffmann-La Roche AG Anti-tpbg antibodies and methods of use
WO2017072662A1 (en) 2015-10-29 2017-05-04 Novartis Ag Antibody conjugates comprising toll-like receptor agonist
TW201730211A (en) 2015-10-30 2017-09-01 建南德克公司 Anti-Factor D antibodies and conjugates
JP2019504617A (en) 2015-11-08 2019-02-21 ジェネンテック, インコーポレイテッド Multispecific antibody screening method
EA201891121A1 (en) 2015-11-19 2018-12-28 Бристол-Майерс Сквибб Компани Antibodies to the glukortikoid-induced receptor of the tumor necrosis factor (gitr) and their applications
WO2017095875A1 (en) 2015-11-30 2017-06-08 Bristol-Myers Squibb Company Anti human ip-10 antibodies and their uses
MX2018006778A (en) 2015-12-04 2018-08-01 Novartis Ag Antibody cytokine engrafted compositions and methods of use for immunoregulation.
US20170198040A1 (en) 2015-12-18 2017-07-13 Novartis Ag ANTIBODIES TARGETING CD32b AND METHODS OF USE THEREOF
EP3405489A1 (en) 2016-01-20 2018-11-28 Genentech, Inc. High dose treatments for alzheimer's disease
EP3411396A1 (en) 2016-02-04 2018-12-12 Curis, Inc. Mutant smoothened and methods of using the same
KR20180119632A (en) 2016-02-29 2018-11-02 제넨테크, 인크. Treatment and Diagnosis Methods for Cancer
AU2017228470A1 (en) 2016-03-04 2018-08-30 Bristol-Myers Squibb Company Combination therapy with anti-CD73 antibodies
CN109195996A (en) 2016-03-08 2019-01-11 中央研究院 The modularity synthetic method of N- glycan and its array
EP3430053A1 (en) 2016-03-14 2019-01-23 Millennium Pharmaceuticals, Inc. Methods of treating or preventing graft versus host disease
AU2017234009A1 (en) 2016-03-14 2018-09-27 Millennium Pharmaceuticals, Inc. Method of preventing graft versus host disease
TW201740975A (en) 2016-03-15 2017-12-01 中外製藥股份有限公司 Methods of treating cancers using PD-1 axis binding antagonists and anti-GPC3 antibodies
CN108884142A (en) 2016-03-16 2018-11-23 梅里麦克制药股份有限公司 Engineering TRAIL use for cancer treatment
CN109641955A (en) 2016-03-22 2019-04-16 国家医疗保健研究所 Anti- claudin-1 antibody of humanization and application thereof
JP2019512523A (en) 2016-03-24 2019-05-16 ミレニアム ファーマシューティカルズ, インコーポレイテッドMillennium Pharmaceuticals, Inc. Methods of treating gastrointestinal immune related adverse events in cancer immunotherapy
WO2017165742A1 (en) 2016-03-24 2017-09-28 Millennium Pharmaceuticals, Inc. Methods of treating gastrointestinal immune-related adverse events in anti-ctla4 anti-pd-1 combination treatments
CN108700598A (en) 2016-03-25 2018-10-23 豪夫迈·罗氏有限公司 The drug of the total antibody of multichannel and antibody conjugate quantifies measuring method
US20170319688A1 (en) 2016-04-14 2017-11-09 Genentech, Inc. Anti-rspo3 antibodies and methods of use
WO2017181079A2 (en) 2016-04-15 2017-10-19 Genentech, Inc. Methods for monitoring and treating cancer
MX2018012492A (en) 2016-04-15 2019-06-06 Genentech Inc Methods for monitoring and treating cancer.
BR112018070934A2 (en) 2016-04-15 2019-02-26 Alpine Immune Sciences Inc immunomodulatory protein variants binders icos and uses thereof
AU2017248830A1 (en) 2016-04-15 2018-10-25 Alpine Immune Sciences, Inc. CD80 variant immunomodulatory proteins and uses thereof
WO2017189724A1 (en) 2016-04-27 2017-11-02 Novartis Ag Antibodies against growth differentiation factor 15 and uses thereof
CA3019524A1 (en) 2016-05-02 2017-11-09 F. Hoffmann-La Roche Ag The contorsbody - a single chain target binder
US20190135928A1 (en) 2016-05-09 2019-05-09 Bristol-Myers Squibb Company Tl1a antibodies and uses thereof
WO2017194441A1 (en) 2016-05-11 2017-11-16 F. Hoffmann-La Roche Ag Modified anti-tenascin antibodies and methods of use
JP2019522633A (en) 2016-05-20 2019-08-15 ジェネンテック, インコーポレイテッド PROTAC antibody conjugates and methods of use
TW201802121A (en) 2016-05-25 2018-01-16 諾華公司 Reversal binding agents for anti-factor XI/XIa antibodies and uses thereof
WO2017205741A1 (en) 2016-05-27 2017-11-30 Genentech, Inc. Bioanalytical method for the characterization of site-specific antibody-drug conjugates
EP3464360A1 (en) 2016-05-27 2019-04-10 Agenus Inc. Anti-tim-3 antibodies and methods of use thereof
US20170348422A1 (en) 2016-06-06 2017-12-07 Genentech, Inc. Silvestrol antibody-drug conjugates and methods of use
EP3468597A1 (en) 2016-06-12 2019-04-17 Millennium Pharmaceuticals, Inc. Method of treating inflammatory bowel disease
KR20190018690A (en) 2016-06-15 2019-02-25 노파르티스 아게 Methods for the treatment of diseases using inhibitors of bone morphogenetic protein 6 (BMP6)
WO2017223405A1 (en) 2016-06-24 2017-12-28 Genentech, Inc. Anti-polyubiquitin multispecific antibodies
JP2019524681A (en) 2016-07-04 2019-09-05 エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft New antibody format
BR112019000431A2 (en) 2016-07-14 2019-07-09 Squibb Bristol Myers Co antibodies against tim3 and their uses
EP3487880A1 (en) 2016-07-25 2019-05-29 Biogen MA Inc. Anti-hspa5 (grp78) antibodies and uses thereof
WO2018022945A1 (en) 2016-07-28 2018-02-01 Alpine Immune Sciences, Inc. Cd112 variant immunomodulatory proteins and uses thereof
US20190175654A1 (en) 2016-07-28 2019-06-13 Alpine Immune Sciences, Inc. Cd155 variant immunomodulatory proteins and uses thereof
CA3027018A1 (en) 2016-07-29 2018-02-01 Chugai Seiyaku Kabushiki Kaisha Bispecific antibody exhibiting increased alternative fviii-cofactor-function activity
NL2017267B1 (en) 2016-07-29 2018-02-01 Aduro Biotech Holdings Europe B V Anti-pd-1 antibodies
NL2017270B1 (en) 2016-08-02 2018-02-09 Aduro Biotech Holdings Europe B V New anti-hCTLA-4 antibodies
CN109790223A (en) 2016-08-05 2019-05-21 阿拉科斯有限责任公司 Anti- SIGLEC-7 antibody for treating cancer
WO2018029124A1 (en) 2016-08-08 2018-02-15 F. Hoffmann-La Roche Ag Therapeutic and diagnostic methods for cancer
WO2018031662A1 (en) 2016-08-11 2018-02-15 Genentech, Inc. Pyrrolobenzodiazepine prodrugs and antibody conjugates thereof
WO2018044970A1 (en) 2016-08-31 2018-03-08 University Of Rochester Human monoclonal antibodies to human endogenous retrovirus k envelope (herv-k) and uses thereof
CN109689682A (en) 2016-09-19 2019-04-26 豪夫迈·罗氏有限公司 Affinity chromatography based on complement factor
AU2017330405A1 (en) 2016-09-23 2019-02-21 Genentech, Inc. Uses of IL-13 antagonists for treating atopic dermatitis
US20190300618A1 (en) 2016-09-26 2019-10-03 Merck Sharp & Dohme Corp. Anti-cd27 antibodies
EP3522933A1 (en) 2016-10-05 2019-08-14 H. Hoffnabb-La Roche Ag Methods for preparing antibody drug conjugates
CA3038712A1 (en) 2016-10-06 2018-04-12 Genentech, Inc. Therapeutic and diagnostic methods for cancer
CN110023337A (en) 2016-10-11 2019-07-16 艾吉纳斯公司 Anti-lag-3 antibody and its application method
WO2018081648A2 (en) 2016-10-29 2018-05-03 Genentech, Inc. Anti-mic antibidies and methods of use
US20190263899A1 (en) 2016-11-14 2019-08-29 Novartis Ag Compositions, methods, and therapeutic uses related to fusogenic protein minion
WO2018093821A1 (en) 2016-11-15 2018-05-24 Genentech, Inc. Dosing for treatment with anti-cd20/anti-cd3 bispecific antibodies
TW201829463A (en) 2016-11-18 2018-08-16 瑞士商赫孚孟拉羅股份公司 Anti-hla-g antibodies and use thereof
AU2017362721A1 (en) 2016-11-19 2019-05-23 Potenza Therapeutics, Inc. Anti-GITR antigen-binding proteins and methods of use thereof
CN110023334A (en) 2016-11-21 2019-07-16 科雅博有限责任公司 Anti- GP73 antibody and immune conjugate
WO2018098363A2 (en) 2016-11-23 2018-05-31 Bioverativ Therapeutics Inc. Bispecific antibodies binding to coagulation factor ix and coagulation factor x
CA3045294A1 (en) 2016-12-07 2018-06-14 Genentech, Inc. Anti-tau antibodies and methods of use
AU2017373944A1 (en) 2016-12-07 2019-06-20 Agenus Inc. Anti-CTLA-4 antibodies and methods of use thereof
EP3551225A1 (en) 2016-12-07 2019-10-16 Agenus Inc. Antibodies and methods of use thereof
CR20190271A (en) 2016-12-07 2019-09-03 Genentech Inc Anti-tau antibodies and methods of use
CA3045495A1 (en) 2016-12-12 2018-06-21 Genentech, Inc. Methods of treating cancer using anti-pd-l1 antibodies and antiandrogens
WO2018115960A1 (en) 2016-12-19 2018-06-28 Mosaic Biomedicals, S.L. Antibodies against lif and uses thereof
AU2017384126A1 (en) 2016-12-20 2019-05-02 F. Hoffmann-La Roche Ag Combination therapy of anti-CD20/anti-CD3 bispecific antibodies and 4-1BB (CD137) agonists
AU2017383232A1 (en) 2016-12-23 2019-06-27 Novartis Ag Factor XI antibodies and methods of use
CA3046313A1 (en) 2016-12-23 2018-06-28 Potenza Therapeutics, Inc. Anti-neuropilin antigen-binding proteins and methods of use thereof
MX2019007795A (en) 2017-01-03 2019-08-16 Hoffmann La Roche Bispecific antigen binding molecules comprising anti-4-1bb clone 20h4.9.
WO2018129029A1 (en) 2017-01-04 2018-07-12 Immunogen, Inc. Met antibodies and immunoconjugates and uses thereof
WO2018129451A2 (en) 2017-01-09 2018-07-12 Merrimack Pharmaceuticals, Inc. Anti-fgfr antibodies and methods of use
SG11201801401UA (en) 2017-01-31 2018-09-27 Chugai Pharmaceutical Co Ltd A pharmaceutical composition for use in the treatment or prevention of a c5-related disease and a method for treating or preventing a c5-related disease
CN110248963A (en) 2017-02-03 2019-09-17 诺华股份有限公司 Anti- CCR7 antibody drug conjugate
AU2018218557A1 (en) 2017-02-08 2019-08-22 Novartis Ag FGF21 mimetic antibodies and uses thereof
AU2018217816A1 (en) 2017-02-10 2019-08-15 Genentech, Inc. Anti-tryptase antibodies, compositions thereof, and uses thereof
CA3051839A1 (en) 2017-02-17 2018-08-23 Bristol-Myers Squibb Company Antibodies to alpha-synuclein and uses thereof
CA3054167A1 (en) 2017-02-27 2018-08-30 Regeneron Pharmaceuticals, Inc. Humanized model of kidney and liver disorders
WO2018160841A1 (en) 2017-03-01 2018-09-07 Genentech, Inc. Diagnostic and therapeutic methods for cancer
WO2018158398A1 (en) 2017-03-02 2018-09-07 INSERM (Institut National de la Santé et de la Recherche Médicale) Antibodies having specificity to nectin-4 and uses thereof
AU2018235838A1 (en) 2017-03-16 2019-09-05 Alpine Immune Sciences, Inc. CD80 variant immunomodulatory proteins and uses thereof
WO2018170021A1 (en) 2017-03-16 2018-09-20 Alpine Immune Sciences, Inc. Pd-l1 variant immunomodulatory proteins and uses thereof
CA3053812A1 (en) 2017-03-16 2018-09-20 Alpine Immune Sciences, Inc. Pd-l2 variant immunomodulatory proteins and uses thereof
AR111249A1 (en) 2017-03-22 2019-06-19 Genentech Inc Antibody compositions optimized for the treatment of eye disorders
AU2018240117A1 (en) 2017-03-24 2019-09-19 Beth Israel Deaconess Medical Center, Inc. Methods for preventing and treating heart disease
SG11201908326YA (en) 2017-03-28 2019-10-30 Genentech Inc Methods of treating neurodegenerative diseases
WO2018178076A1 (en) 2017-03-29 2018-10-04 F. Hoffmann-La Roche Ag Bispecific antigen binding molecule for a costimulatory tnf receptor
WO2018178055A1 (en) 2017-03-29 2018-10-04 F. Hoffmann-La Roche Ag Bispecific antigen binding molecule for a costimulatory tnf receptor
AU2018243665A1 (en) 2017-03-30 2019-09-26 Potenza Therapeutics, Inc. Anti-TIGIT antigen-binding proteins and methods of use thereof
WO2018185618A1 (en) 2017-04-03 2018-10-11 Novartis Ag Anti-cdh6 antibody drug conjugates and anti-gitr antibody combinations and methods of treatment
SG11201908787WA (en) 2017-04-04 2019-10-30 Hoffmann La Roche Novel bispecific antigen binding molecules capable of specific binding to cd40 and to fap
CN110392698A (en) 2017-04-05 2019-10-29 豪夫迈·罗氏有限公司 Anti- LAG3 antibody
US20180326054A1 (en) 2017-04-05 2018-11-15 Hoffmann-La Roche Inc. Bispecific antibodies specifically binding to pd1 and lag3
TW201839014A (en) 2017-04-07 2018-11-01 美商默沙東藥廠 Anti-ilt4 antibodies and antigen-binding fragments
US20180312587A1 (en) 2017-04-13 2018-11-01 Aduro Biotech Holdings, Europe B.V. Anti-sirp alpha antibodies
WO2018191502A2 (en) 2017-04-13 2018-10-18 Agenus Inc. Anti-cd137 antibodies and methods of use thereof
AU2018251993A1 (en) 2017-04-14 2019-10-24 Genentech, Inc. Diagnostic and therapeutic methods for cancer
US20190078160A1 (en) 2017-04-21 2019-03-14 Genentech, Inc. Use of klk5 antagonists for treatment of a disease
WO2018201096A1 (en) 2017-04-27 2018-11-01 Tesaro, Inc. Antibody agents directed against lymphocyte activation gene-3 (lag-3) and uses thereof
CA3061320A1 (en) 2017-04-28 2018-11-01 Millennium Pharmaceuticals, Inc. Method of treating pediatric disorders
AR111651A1 (en) 2017-04-28 2019-08-07 Novartis Ag Antibody Conjugates comprising receptor agonists toll-like and combination therapies
WO2018204363A1 (en) 2017-05-01 2018-11-08 Agenus Inc. Anti-tigit antibodies and methods of use thereof
WO2018213097A1 (en) 2017-05-15 2018-11-22 University Of Rochester Broadly neutralizing anti-influenza monoclonal antibody and uses thereof
WO2018215936A1 (en) 2017-05-24 2018-11-29 Novartis Ag Antibody-cytokine engrafted proteins and methods of use in the treatment of cancer
UY37738A (en) 2017-05-24 2019-01-02 Novartis Ag Proteins grafted antibody-cytokine and methods of use for immune related disorders
WO2018215938A1 (en) 2017-05-24 2018-11-29 Novartis Ag Antibody-cytokine engrafted proteins and methods of use
WO2018215937A1 (en) 2017-05-24 2018-11-29 Novartis Ag Interleukin-7 antibody cytokine engrafted proteins and methods of use in the treatment of cancer
AU2018272852A1 (en) 2017-05-25 2019-11-28 Bristol-Myers Squibb Company Antibodies comprising modified heavy constant regions
WO2018220446A1 (en) 2017-06-01 2018-12-06 Compugen Ltd. Triple combination antibody therapies
UY37758A (en) 2017-06-12 2019-01-31 Novartis Ag Method for making bispecific antibodies, bispecific antibodies and therapeutic use of such antibodies
WO2018229715A1 (en) 2017-06-16 2018-12-20 Novartis Ag Compositions comprising anti-cd32b antibodies and methods of use thereof
WO2018229706A1 (en) 2017-06-16 2018-12-20 Novartis Ag Combination therapy for the treatment of cancer
US20190062428A1 (en) 2017-06-19 2019-02-28 Surface Oncology, Inc. Combination of anti-cd47 antibodies and cell death-inducing agents, and uses thereof
AU2018288854A1 (en) 2017-06-20 2019-11-21 Amgen Inc. Method of treating or ameliorating metabolic disorders using binding proteins for gastric inhibitory peptide receptor (GIPR) in combination with GLP-1 agonists
TW201919709A (en) 2017-06-23 2019-06-01 美商維洛斯生物公司 ROR1 antibody immunoconjugates
TW201906865A (en) 2017-06-28 2019-02-16 瑞士商諾華公司 Prevention and treatment of urinary incontinence
WO2019018757A1 (en) 2017-07-21 2019-01-24 Genentech, Inc. Therapeutic and diagnostic methods for cancer
US20190119396A1 (en) 2017-07-26 2019-04-25 Forty Seven, Inc. Anti-SIRP-Alpha Antibodies and Related Methods
WO2019033043A2 (en) 2017-08-11 2019-02-14 Genentech, Inc. Anti-cd8 antibodies and uses thereof
WO2019036605A2 (en) 2017-08-17 2019-02-21 Massachusetts Institute Of Technology Multiple specificity binders of cxc chemokines and uses thereof
TW201920279A (en) 2017-08-25 2019-06-01 美商戊瑞治療有限公司 B7-H4 antibodies and methods of use thereof
WO2019059411A1 (en) 2017-09-20 2019-03-28 Chugai Seiyaku Kabushiki Kaisha Dosage regimen for combination therapy using pd-1 axis binding antagonists and gpc3 targeting agent
WO2019074983A1 (en) 2017-10-10 2019-04-18 Alpine Immune Sciences, Inc. Ctla-4 variant immunomodulatory proteins and uses thereof
US20190144549A1 (en) 2017-10-10 2019-05-16 Tilos Therapeutics, Inc. Anti-lap antibodies and uses thereof
TW201925223A (en) 2017-10-18 2019-07-01 美商艾爾潘免疫科學有限公司 Variant ICOS ligand immunomodulatory proteins and related compositions and methods
TW201932142A (en) 2017-10-20 2019-08-16 瑞士商赫孚孟拉羅股份公司 Method for generating multispecific antibodies from monospecific antibodies
WO2019081983A1 (en) 2017-10-25 2019-05-02 Novartis Ag Antibodies targeting cd32b and methods of use thereof
TW201932494A (en) 2017-10-30 2019-08-16 瑞士商赫孚孟拉羅股份公司 Method for in vivo generation of multispecific antibodies from monospecific antibodies
WO2019089753A2 (en) 2017-10-31 2019-05-09 Compass Therapeutics Llc Cd137 antibodies and pd-1 antagonists and uses thereof
WO2019090263A1 (en) 2017-11-06 2019-05-09 Genentech, Inc. Diagnostic and therapeutic methods for cancer
WO2019100052A2 (en) 2017-11-20 2019-05-23 Compass Therapeutics Llc Cd137 antibodies and tumor antigen-targeting antibodies and uses thereof
WO2019102353A1 (en) 2017-11-22 2019-05-31 Novartis Ag Reversal binding agents for anti-factor xi/xia antibodies and uses thereof
WO2019106578A2 (en) 2017-12-01 2019-06-06 Novartis Ag Polyomavirus neutralizing antibodies
WO2019110823A1 (en) 2017-12-08 2019-06-13 Argenx Bvba Use of fcrn antagonists for treatment of generalized myasthenia gravis
WO2019126133A1 (en) 2017-12-20 2019-06-27 Alexion Pharmaceuticals, Inc. Liquid formulations of anti-cd200 antibodies
WO2019126536A1 (en) 2017-12-20 2019-06-27 Alexion Pharmaceuticals Inc. Humanized anti-cd200 antibodies and uses thereof
EP3502140A1 (en) 2017-12-21 2019-06-26 F. Hoffmann-La Roche AG Combination therapy of tumor targeted icos agonists with t-cell bispecific molecules
US20190211098A1 (en) 2017-12-22 2019-07-11 Genentech, Inc. Use of pilra binding agents for treatment of a disease
WO2019129679A1 (en) 2017-12-29 2019-07-04 F. Hoffmann-La Roche Ag Method for improving vegf-receptor blocking selectivity of an anti-vegf antibody
WO2019136179A1 (en) 2018-01-03 2019-07-11 Alpine Immune Sciences, Inc. Multi-domain immunomodulatory proteins and methods of use thereof
WO2019134981A1 (en) 2018-01-05 2019-07-11 Ac Immune Sa Misfolded tdp-43 binding molecules
WO2019140229A1 (en) 2018-01-12 2019-07-18 Bristol-Myers Squibb Company Antibodies against tim3 and uses thereof
WO2019143636A1 (en) 2018-01-16 2019-07-25 Lakepharma, Inc. Bispecific antibody that binds cd3 and another target
WO2019148020A1 (en) 2018-01-26 2019-08-01 Genentech, Inc. Compositions and methods of use
WO2019148026A1 (en) 2018-01-26 2019-08-01 Genentech, Inc. Il-22 fc fusion proteins and methods of use
WO2019148412A1 (en) 2018-02-01 2019-08-08 Merck Sharp & Dohme Corp. Anti-pd-1/lag3 bispecific antibodies
US20190270814A1 (en) 2018-02-08 2019-09-05 Genentech, Inc. Bispecific antigen-binding molecules and methods of use
WO2019157358A1 (en) 2018-02-09 2019-08-15 Genentech, Inc. Therapeutic and diagnostic methods for mast cell-mediated inflammatory diseases
WO2019158645A1 (en) 2018-02-14 2019-08-22 Abba Therapeutics Ag Anti-human pd-l2 antibodies
WO2019165140A1 (en) 2018-02-21 2019-08-29 Genentech, Inc. DOSING FOR TREATMENT WITH IL-22 Fc FUSION PROTEINS
WO2019165434A1 (en) 2018-02-26 2019-08-29 Genentech, Inc. Dosing for treatment with anti-tigit and anti-pd-l1 antagonist antibodies
NL2020520B1 (en) 2018-03-02 2019-09-12 Labo Bio Medical Invest B V Multispecific binding molecules for the prevention, treatment and diagnosis of neurodegenerative disorders
WO2019175071A1 (en) 2018-03-13 2019-09-19 F. Hoffmann-La Roche Ag Therapeutic combination of 4-1 bb agonists with anti-cd20 antibodies
WO2019178316A1 (en) 2018-03-14 2019-09-19 Genentech, Inc. Anti-klk5 antibodies and methods of use
WO2019183040A1 (en) 2018-03-21 2019-09-26 Five Prime Therapeutics, Inc. ANTIBODIES BINDING TO VISTA AT ACIDIC pH
WO2019191552A1 (en) 2018-03-29 2019-10-03 Genentech, Inc. Modulating lactogenic activity in mammalian cells
WO2019195126A1 (en) 2018-04-02 2019-10-10 Bristol-Myers Squibb Company Anti-trem-1 antibodies and uses thereof
WO2019195514A1 (en) 2018-04-04 2019-10-10 Genentech, Inc. Methods for detecting and quantifying fgf21
EP3552631A1 (en) 2018-04-10 2019-10-16 Inatherys Antibody-drug conjugates and their uses for the treatment of cancer
WO2019197903A1 (en) 2018-04-12 2019-10-17 Mosaic Biomedicals Slu Combination of lif inhibitors and pd-1 axis inhibitors for use in treating cancer
WO2019200357A1 (en) 2018-04-12 2019-10-17 Surface Oncology, Inc. Biomarker for cd47 targeting therapeutics and uses therefor
WO2019202041A1 (en) 2018-04-18 2019-10-24 F. Hoffmann-La Roche Ag Multispecific antibodies and use thereof
WO2019202040A1 (en) 2018-04-18 2019-10-24 F. Hoffmann-La Roche Ag Anti-hla-g antibodies and use thereof
WO2019213384A1 (en) 2018-05-03 2019-11-07 University Of Rochester Anti-influenza neuraminidase monoclonal antibodies and uses thereof
WO2019220204A2 (en) 2018-05-14 2019-11-21 Mosaic Biomedicals Slu Antibodies against lif and dosage forms thereof

Also Published As

Publication number Publication date
CA2163345A1 (en) 1994-12-22
WO1994029351A2 (en) 1994-12-22
JPH08511420A (en) 1996-12-03
EP0714409A1 (en) 1996-06-05
AU691811B2 (en) 1998-05-28
WO1994029351A3 (en) 1994-12-22

Similar Documents

Publication Publication Date Title
AU689809B2 (en) Quinolizinone type compounds
AU696235C (en) Anti-GP39 antibodies and uses therefor
AU703110C (en) Modified factor VII
AU684570B2 (en) Ultramulsions
AU695850B2 (en) Poly-beta -1-4-N-acetylglucosamine
AU5267190A (en) Modified antibodies
AU1642795A (en) Substituted pyridylpyrazoles
AU6072994A (en) Tri-carbamate-functional crosslinking agents
AU5883694A (en) Device
AU4036895A (en) Substituted 1H-imidazoles
AU7101094A (en) Factor ix - polymeric conjugates
AU6029594A (en) Factor viii - polymeric conjugates
AU7895094A (en) Imidazopyridazine
AU6743894A (en) Truss
AU1157195A (en) 4-amino-1-piperidylbenzoylguanidine
AU6032194A (en) Parameterized neurocontrollers
AU2464892A (en) Assay method
AU4042195A (en) Anti-alphaV-integrin monoclonal antibody
AU5009396A (en) Containers
AUPN354595A0 (en) Novel materials
AU7587696A (en) Differentiation-suppressive polypeptide
AU2028695A (en) Oxalylamino-benzofuran- and benzothienyl-derivatives
AU6508194A (en) Transintimal recanalisation device
AU6785996A (en) 2-alkylpyrrolidines
AU7190094A (en) Electrofilter

Legal Events

Date Code Title Description
MK14 Patent ceased section 143(a) (annual fees not paid) or expired